Noble Capital Markets Research Morning Call

Noble Capital Markets Research Report Monday, November 3, 2025

Companies contained in today’s report:

ACCO Brands (ACCO)/OUTPERFORM – A Mixed Quarter
DLH Holdings (DLHC)/OUTPERFORM – Some Good, Some Not So Good
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Looking Forward To Phase 3 Data Presentation This Week

ACCO Brands (ACCO/$3.76 | Price Target: $9)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Mixed Quarter
Rating: OUTPERFORM

Soft Environment. ACCO’s third quarter operating results continue to reflect a soft end market environment, with reported revenue below expectations. However, the Company delivered third quarter adjusted EPS in line with the outlook and expanded gross margin by 50 basis points as the Company continued to demonstrate strong operational discipline through ongoing execution of the $100 million cost reduction program.

Financials. Revenue of $383.7 million was down 8.8% from $420.9 million in 3Q24, modestly below management’s expected decline of 5-8%. We were at $392 million. Comp sales were down 10.3%, reflecting softer global demand. Adjusted net income was $19.5 million, compared with adjusted net income of $22.5 million in 2024, and adjusted earnings per share were $0.21, within the $0.21-$0.24 guide, but down from $0.23 in 2024. We had estimated adjusted EPS of $0.23.

Get the Full Report

DLH Holdings (DLHC/$6.22 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Good, Some Not So Good
Rating: OUTPERFORM

New Data. DLH filed an 8-K disclosing some preliminary financial data for the fiscal year ended September 30, 2025, and updates on its CMOP (the good) and Head Start (not so good) contracts. Bad news first: DLH has lost the Head Start contract, which went to a small business. This contract generated $40 million of revenue in fiscal 2024 and $28.4 million in the first nine months of fiscal 2025. With the government shutdown ongoing, the status of protests from unsuccessful bidders is unclear.

CMOP. On the positive side, DLH has been awarded a sole-source ID/IQ to continue providing pharmacy and logistics services for 4 CMOP locations. The contract has a ceiling value of $90 million and has a maximum performance period through April 2027. The Company expects the quarterly revenue contribution from these contracts to be approximately $28 million, in-line with current revenue volume on this contract.

Get the Full Report

Gyre Therapeutics, Inc (GYRE/$7.75 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Looking Forward To Phase 3 Data Presentation This Week
Rating: OUTPERFORM

Phase 3 Data To Be Presented At A Medical Meeting. Presentation of data from the Hydronidone Phase 3 trial is scheduled for Friday, November 7,2025 at the The Liver Meeting, the annual conference of the American Association for the Study of Liver Disease (AASLD). This presentation is expected to give detailed clinical data on the actions Hydronidone in liver fibrosis associated with chronic hepatitis B infection. We see this indication as proof of concept as well as a revenue opportunity.

We Expect Additional Clinical Trial Details To Be Presented. The Phase 3 trial met its primary endpoint of regression of liver fibrosis, with treated patients showing a regression rate of 52.85% compared with a placebo patient rate of 29.84% (p=0.0002). This reduction compared with placebo is both statistically significant and clinically meaningful. An important secondary endpoint, reduction in inflammation, also showed meaningful improvement.

Get the Full Report

Noble Capital Markets Research Report Friday, October 31, 2025

Companies contained in today’s report:

1-800-Flowers.com (FLWS)/MARKET PERFORM – Likely To Be A Bumpy Ride In The Near Term
Cumulus Media (CMLS)/MARKET PERFORM – National Advertising Perplexingly Weak
NN (NNBR)/OUTPERFORM – Moving Forward With Transformation

1-800-Flowers.com (FLWS/$3.62)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Likely To Be A Bumpy Ride In The Near Term
Rating: MARKET PERFORM

Q1 Results. The company reported Q1 revenue of $215.2 million, and an adj. EBITDA loss of $32.9 million, both of which were largely in line with our estimates of $217.9 million and a loss of $33.0 million, respectively. Revenue decreased 11.1% over the prior year period, in part, driven by the company’s strategic decision to focus on positive marketing contribution.

Focused on profitability. In an effort to mitigate the impact of tariffs and soft demand, there is a focus on reducing costs and maintaining stable profitability. As such, operating expenses were $127.3 million in the quarter, down $12 million y-o-y. When excluding non-recurring charges and deferred compensation effects, operating expenses were $124.9 million. The operational expense reductions were driven by a 15.8% reduction in marketing spend, reduced labor costs, and early progress from the company’s efficiency initiatives.

Get the Full Report

Cumulus Media (CMLS/$0.1034)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
National Advertising Perplexingly Weak
Rating: MARKET PERFORM

Q3 beats our downcast expectations. Q3 revenue of $180.3 million and adj. EBITDA of $16.7 million, both of which were modestly better than our estimates of $179.0 million and $12.9 million, respectively. Third quarter revenues declined 11.5% from the prior period, adversely affected by the absence of $3.6 million in Political advertising and the absence of The Daily Wire and The Dan Bongino Show. 

DMS remains a bright spot. The Digital Marketing Services (DMS) business remains a bright spot, with revenue surging 34% in the quarter. Notably, the digital segment now represents approximately 50% of total digital segment revenue, helping to offset persistent weakness in the core broadcast radio business.

Get the Full Report

NN (NNBR/$1.63 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Moving Forward With Transformation
Rating: OUTPERFORM

3Q25. NN reported 3Q25 results that were below expectations, although there were some y-o-y improvements. Revenue of $103.9 million was down 8.5% y-o-y on a reported basis and down 4.4% on a pro forma basis. We had projected $115 million, and the consensus was $112 million. Gross margin rose to 16.8% and 18.8% on an adjusted basis, up from 14.5% and 16.8%, respectively, in 3Q24. Adjusted EBITDA grew to $12.4 million, or an 11.9% margin, up from $11.6 million and 10.2% last year. We had forecast $13.6 million. Adjusted net loss was $0.01/sh. We and consensus were at EPS of $0.01.

New Business. NN reported third quarter new business wins of  $11.3 million, led by strategic wins in  North America auto, fire protection, and aerospace and defense products. YTD, the Company has won  $44.4 million of new business. Management’s goal remains to win $60-$70 million annually.

Get the Full Report

Noble Capital Markets Research Report Wednesday, October 29, 2025

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Third Quarter Results Exceed Our Expectations
Aurania Resources (AUIAF)/OUTPERFORM – Establishing a Toehold in Critical Metals
InPlay Oil (IPOOF)/OUTPERFORM – Soft Commodity Pricing Drives Estimate Revisions
MariMed Inc (MRMD)/OUTPERFORM – Exiting Missouri
Perfect (PERF)/OUTPERFORM – Turning the Corner to Operating Profit
Travelzoo (TZOO)/OUTPERFORM – Hits A Little Turbulence On Its Ascent
Unicycive Therapeutics (UNCY)/OUTPERFORM – Resubmission For Approval Expected Before Year-End 2025

Alliance Resource Partners (ARLP/$24.31 | Price Target: $33)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Third Quarter Results Exceed Our Expectations
Rating: OUTPERFORM

Third quarter financial results. Alliance reported third quarter adjusted EBITDA and earnings per unit (EPU) of $185.8 million and $0.73, respectively, compared to $170.4 million and $0.66 during the prior year period. We had projected EBITDA and EPU of $176.2 million and $0.68. Total revenue amounted to $571.4 million compared to $613.6 million during the prior year period and our $577.9 million estimate. While revenue from coal sales exceeded our estimate, oil and gas royalties, transportation, and other revenues were below. Third quarter results benefited from expenses that were lower than our estimates and contributions from equity method investments and the change in value of ARLP’s digital assets.

Outlook for the remainder of 2025 and 2026. Management updated its 2025 guidance. Within ARLP’s coal operation, guidance ranges were narrowed. Total sales are expected to be between 32.50 million tons and 33.25 million tons compared to prior guidance of between 32.75 million tons and 34.0 million tons. Within the oil and gas royalty segment, volumes were lowered to reflect the timing of a multi-well pad in the Delaware Basin of the Permian, which is expected to come online in early 2026.

Get the Full Report

Aurania Resources (AUIAF/$0.18 | Price Target: $0.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Establishing a Toehold in Critical Metals
Rating: OUTPERFORM

Potential critical metals recovery project. Aurania Resources Ltd. executed a Memorandum of Understanding (MOU) with the Society for the Remediation and Environmental Development of the former Balangero asbestos mine, otherwise known as RSA, and Firestone Ventures Inc. Dr. Keith Barron, Aurania’s Chief Executive Officer and director, is the President and Director of Firestone. The MOU allows for data collection and sampling of tailings at the former Balangero mine, which operated from 1916 to 1990, and is near Turin, Italy. Aurania will evaluate the tailings to recover nickel and cobalt, two critical metals for electric battery production.

Pathway to a commercial agreement. The MOU has a one-year term, and if results prove favorable, the parties are expected to enter into a commercial agreement to extract metals from the waste piles. Firestone would then conduct carbon capture on the waste stream, using industrial carbon dioxide to neutralize the contained asbestos and convert it into a useful form of carbon. Aurania and Firestone have exclusive access to the site for this evaluation.

Get the Full Report

InPlay Oil (IPOOF/$8.7 | Price Target: $13)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Soft Commodity Pricing Drives Estimate Revisions
Rating: OUTPERFORM

Updating third quarter 2025 estimates. While we are maintaining our third-quarter production forecast of 18,695 barrels of oil equivalent per day (boe/d), we lowered our third-quarter 2025 revenue, adjusted funds flow (AFF), and AFF per share estimates to C$86.8 million, C$28.0 million, and C$1.00, respectively, from C$89.3 million, C$38.9 million, and C$1.39. These changes reflect modestly lower commodity pricing, along with higher royalty costs and operating expenses. We expect third-quarter operating expenses to be elevated due to turnaround activity and downtime associated with the recently completed gas plant expansion.

Revising full-year 2025 estimates. For the full year 2025, we forecast revenue of C$301.9 million, AFF of C$116.3 million, and AFF per share of C$4.71, compared to prior estimates of C$306.7 million, C$131.8 million, and C$5.34. These reductions primarily reflect a weaker pricing environment, partially offset by a modest increase in our full-year production forecast to 16,851 boe/d from 16,800, driven by higher fourth quarter production expectations.

Get the Full Report

MariMed Inc (MRMD/$0.13 | Price Target: $0.25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Exiting Missouri
Rating: OUTPERFORM

An Exit. As noted in its 2Q25 call, MariMed undertook a review of its Missouri operations and has determined to exit the market, effective immediately. Exiting Missouri is expected to improve the Company’s overall financial performance, particularly gross margin and adjusted EBITDA, and allow management to focus resources on higher return opportunities, such as markets where the Company has established retail and wholesale operations.

Background. Since 2024, the Company has managed the Missouri operations of another licensed cannabis operator and distributed certain of its brands there under a Managed Services and Licensing Agreement, while awaiting license transfer approval from the state. The Company only began generating revenue in Missouri at the tail-end of 2024. While MariMed’s brands performed well where available, reaching scale in the state would require significant resources, resources that management believes can be better utilized in its core markets. Nonetheless, the Company will consider licensing opportunities in Missouri with a vertical operator.

Get the Full Report

Perfect (PERF/$2.05 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Turning the Corner to Operating Profit
Rating: OUTPERFORM

Q3 beat. Perfect reported Q3 revenue of $18.7 million, up 15.7% Y/Y and above our estimate of $17.8 million, with adj. EBITDA of $1.2 million, double expectations. Revenue growth was led by strong B2C performance. The company also achieved its first quarter of operating profit, reflecting greater scale efficiency and disciplined cost control.

Continued strength in B2C. YouCam subscribers totaled 946K, down slightly, likely due to price hikes that the company initiated, which have led to higher revenue per user. B2C strength remains solid, supported by the YouCam AI Agent, which links apps under a unified login to personalize experiences and increase retention. Two apps are integrated, with full rollout expected by year-end.

Get the Full Report

Travelzoo (TZOO/$8.31 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Hits A Little Turbulence On Its Ascent
Rating: OUTPERFORM

Softer than expected Q3 Results. The company reported Q3 revenue of $22.2 million, an increase of a solid 10.4%, and adj. EBITDA of $0.9 million, both of which were below our estimates of $23.0 million and $2.9 million, respectively. Importantly, the modestly softer than expected results were largely driven by weakness in advertising and increased marketing spend on customer acquisition.

Customer acquisition. Notably, in Q3, customer acquisition costs increased to $40 per customer, up from $38 in Q2 and $28 in Q1, reflecting the company’s strategic efforts to grow its subscriber base. Furthermore, despite higher acquisition spend per customer, return on spend remains positive. Total return per customer in Q3 was $55, which consists of $40 from annual subscription fees and $15 from in-quarter transactions. While this strategy impacted adj. EBITDA in Q3, it’s supportive of a favorable long term growth outlook.

Get the Full Report

Unicycive Therapeutics (UNCY/$4.72 | Price Target: $60)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Resubmission For Approval Expected Before Year-End 2025
Rating: OUTPERFORM

Unicycive Expects To Resubmit Its Application Before YE2025. Unicycive announced plans to resubmit its application for OLC (oxylanthanum carbonate) approval before the end of 2025. This follows a meeting with the FDA to identify and resolve issues that resulted in the Complete Response Letter (CRL) in June 2025. This timeframe is consistent with our expectations for resubmission. We continue to expect OLC to be approved by mid-2026.

Resubmission Announcement Follows An FDA Meeting. In early June 2025, Unicycive announced that a manufacturing inspection found deficiencies at a contract manufacturer’s facility. These inspections were one of the last steps toward approval of the New Drug Application (NDA), but the findings stopped the review process. Following the announcement, the company received a CRL on its PDUFA date of June 30, 2025.

Get the Full Report

Noble Capital Markets Research Report Tuesday, October 28, 2025

Companies contained in today’s report:

Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Some Debt Restructuring
The Beachbody Company (BODI)/OUTPERFORM – Strong Brands To Flex Toward Growth

Great Lakes Dredge & Dock (GLDD/$11.03 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Debt Restructuring
Rating: OUTPERFORM

Debt Restructuring. Yesterday, Great Lakes announced it completed an amendment to its existing Revolving Credit Facility, upsizing the facility by $100 million to $430 million and extending its maturity to October 2030 from June of 2029. We believe the expansion of Great Lakes’ revolving credit facility highlights the strength of the Company’s business and its credit profile.

Second Lien Payoff. Significantly, as part of this transaction, the Company utilized the increased revolver capacity to fully repay the $100 million second lien notes issued in 2024. This will save the Company some $6 million per year in interest expense. Great Lakes’ balance sheet remain solid, with no debt maturities until 2029 and a weighted average interest rate now under 6%.

Get the Full Report

The Beachbody Company (BODI/$5.08 | Price Target: $12)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Strong Brands To Flex Toward Growth
Rating: OUTPERFORM

Initiating with an Outperform rating. After years of revenue declines, we believe that the company is on the cusp of a swing toward revenue growth, offering a breakout opportunity for a stock that has been range-bound. We are initiating coverage with an Outperform rating and a $12 price target. 

Well-recognized brands with growth potential. The company has established brands in workout videos, such as Insanity and P90x, and nutritional supplements, including Shakeology, Beachbar, and Beachbody Performance. Such strong brands are expected to support the company’s revenue growth initiatives as it expands distribution of its products into mass merchants. 

Get the Full Report

Noble Capital Markets Research Report Friday, October 24, 2025

Companies contained in today’s report:

MariMed Inc (MRMD)/OUTPERFORM – A Move Into New York

MariMed Inc (MRMD/$0.1426 | Price Target: $0.25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Move Into New York
Rating: OUTPERFORM

New York. Continuing its market expansion, MariMed announced a licensing agreement with Farm 2 Hand, LLC, a New York State cannabis license holder, that will introduce the Company’s top-selling portfolio of products throughout New York State. Terms of the agreement were not disclosed. This expansion follows on the heels of the earlier Pennsylvania and Maine expansions, significantly increasing MariMed’s total addressable market, in our view.

Details. Farm 2 Hand intends to manufacture and distribute a variety of MariMed’s edible products as permitted under New York regulations. Those are initially expected to include Betty’s Eddies fruit chews, Bubby’s Baked goods, and InHouse gummies. The products will be produced in a new kitchen that MariMed will design and equip for Farm 2 Hand at Farm 2 Hand’s Bronx production facility.

Get the Full Report

Noble Capital Markets Research Report Thursday, October 23, 2025

Companies contained in today’s report:

Cocrystal Pharma (COCP)/OUTPERFORM – Highlights From Noble’s Virtual Conference
Hemisphere Energy (HMENF)/OUTPERFORM – Adjusting Our Third Quarter and Full Year 2025 Estimates
Nutriband (NTRB)/OUTPERFORM – Highlights From Noble’s Virtual Conference
Superior Group of Companies (SGC)/OUTPERFORM – Looking Beyond The Third Quarter
The Oncology Institute, Inc. (TOI)/OUTPERFORM – Highlights From Noble’s Virtual Conference

Cocrystal Pharma (COCP/$1.03 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

Proprietary Technology & Drug Design. James Wilson, Chief Financial Officer and Co-CEO, participated in Noble’s Virtual Emerging Growth Conference on October 8th & 9th. The discussion focused on the company’s core technology to design antiviral compounds that bind to highly conserved, essential areas of the viral replication machinery, as well as progress updates on the product pipeline.The full video may be viewed here.

Lead Program & Near-Term Catalyst In Norovirus. The company’s most advanced program is CDI-988, an oral drug for norovirus. This lead indication was chosen strategically because there are no approved vaccines or therapeutics for norovirus. The market is significant, with a stated $60 billion annual market opportunity.

Get the Full Report

Hemisphere Energy (HMENF/$1.45 | Price Target: $2.45)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Adjusting Our Third Quarter and Full Year 2025 Estimates
Rating: OUTPERFORM

Third quarter estimate update. We have trimmed our third-quarter revenue and net income estimates to C$21.6 million and C$6.9 million, respectively, from C$23.5 million and C$7.5 million. Additionally, we have lowered our adjusted funds flow (AFF) and AFF per share estimates to C$10.0 million and C$0.10, respectively, from C$10.7 million and C$0.11.

Full-year estimate changes. For the full year 2025, we project revenues and net income of C$93.7 million and C$27.4 million, respectively, compared to our previous estimates of C$97.7 million and C$29.6 million. Moreover, we have lowered our AFF and AFF per share estimates to C$41.0 million and C$0.41, respectively, from C$43.3 million and C$0.43.

Get the Full Report

Nutriband (NTRB/$7.04 | Price Target: $15)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

Nutriband Is Developing Transdermal Abuse-Deterrent Technologies. Nutriband has developed abuse-deterrent technology for dermal patch drug delivery. Serguei Melnik, Interim CEO, and Irina Gram, Director, highlighted the company’s platform, known as AVERSA, and its focus on patches containing FDA-approved drugs. The presentation may be viewed here.

Lead Product & Market Opportunity. The lead product, AVERSA Fentanyl, is an abuse-deterrent fentanyl patch. Upon approval, the FDA could mandate such technology for all fentanyl patches, the same way it required opioid pills to have abuse-deterrents. Market analysis by Advanced Health projects annual sales of $200 million for the branded AVERSA Fentanyl. If the abuse-resistant patch were mandated and replaced generic patches, sales could reach $800 million. A patch  with improved safety and abuse-deterrence could reverse the decline in fentanyl prescriptions caused by reluctance to prescribe a drug with known abuse potential.

Get the Full Report

Superior Group of Companies (SGC/$10.19 | Price Target: $16)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Looking Beyond The Third Quarter
Rating: OUTPERFORM

Q3 Preview. We expect that there will be some impact on the third quarter from the “pull forward” in Branded Product revenue into the second quarter as consumers reacted ahead of possible trade policy changes. As such, we are modestly lowering our Q3 revenue and earnings expectations, highlighted in Figure #1 Q3 Revisions. 

Largest variance. The largest adjustment to our Q3 revenue estimate is in Branded Products, revised from $89.8 million to $85.0 million. In our view, this segment offers one of the largest upside surprise potential in Q4, which could benefit from an improving macro economy. 

Get the Full Report

The Oncology Institute, Inc. (TOI/$4.39 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

TOI Is Addressing The Unsustainable Cost Trend In Oncology. The Oncology Institute manages medical clinics that have improved outcomes and patient satisfaction while reducing the cost of cancer treatment. Dr. Daniel Virnich, CEO, and Rob Carter, CFO, highlighted the benefits of the company’s hybrid model of employed physicians and contracted independent community oncologists. The video of the company’s presentation may be viewed here

Differentiated Competitive Advantage. TOI distinguishes itself from competitors in the value-based oncology field through its ownership of clinical assets (employed physicians and clinics). This provides greater control over care delivery compared to pure utilization management firms (such as Evolent’s New Century Health) or care navigation models (such as Thyme Care). This control enables higher compliance with value-based prescribing pathways, better integration of ancillary services, and more predictable and significant cost savings for payers.

Get the Full Report

Noble Capital Markets Research Report Tuesday, October 21, 2025

Companies contained in today’s report:

Century Lithium Corp. (CYDVF)/OUTPERFORM – Angel Island’s Commercial Appeal Grows with Lithium Hydroxide Production
Graham (GHM)/MARKET PERFORM – A Tuck In Acquisition
Twin Hospitality (TWNP)/OUTPERFORM – A High-Growth, Asset Light Restaurant Franchisor

Century Lithium Corp. (CYDVF/$0.2 | Price Target: $2.3)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Angel Island’s Commercial Appeal Grows with Lithium Hydroxide Production
Rating: OUTPERFORM

Century produces high-purity lithium hydroxide. Century Lithium produced its first samples of lithium hydroxide from lithium carbonate derived from Angel Island’s lithium claystone deposit and treated at its demonstration plant using the company’s patent-pending alkaline leach and direct lithium extraction (DLE) process. Century had previously focused on making lithium carbonate. By producing high-purity lithium hydroxide, Century has demonstrated an ability to produce another major lithium product for the domestic market.

Pursuing a direct lithium conversion process. Lithium hydroxide samples were produced onsite in a batch process using conventional liming conversion with calcium hydroxide to produce lithium hydroxide with a purity level of 99.5% or greater. Century is pursuing a direct lithium conversion (DLC) process to produce lithium hydroxide directly from lithium chloride solution, which would bypass producing lithium carbonate in an intermediate stage to simplify the process and reduce energy consumption and operating costs.

Get the Full Report

Graham (GHM/$61.81)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Tuck In Acquisition
Rating: MARKET PERFORM

An Acquisition. Yesterday, after the market close, Graham announced the acquisition of certain specified assets of Xdot Bearing Technologies (“Xdot”), a specialized consulting, design, and engineering firm focused on foil bearing technology. While the acquisition price was not revealed, Graham noted Xdot has annual sales of approximately $1 million and is expected to be slightly accretive to the Company’s fiscal year 2026 GAAP net income.

Xdot. Xdot has developed and patented a breakthrough foil bearing design that delivers superior performance while lowering development and production costs. Xdot’s products are complementary to the existing product portfolio of Graham’s Barber-Nichols (BN) subsidiary and will expand capabilities within BN. Notably, Dr. Erik Swanson, Founder, President, and Chief Engineer of Xdot is a world renowned expert in foil bearing analysis, application, and fabrication and will join the BN team upon closing.

Get the Full Report

Twin Hospitality (TWNP/$3.89 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A High-Growth, Asset Light Restaurant Franchisor
Rating: OUTPERFORM

Initiation. We are initiating equity research coverage on Twin Hospitality Group with an Outperform rating and $10 price target. Twin Hospitality is a franchisor and operator of two specialty casual dining restaurant concepts: Twin Peaks and Smokey Bones. The Company is a high-growth, asset light restaurant franchisor with a compelling franchisee value proposition, in our view. On January 29, 2025, parent company FAT Brands distributed approximately 5% of Twin Hospitality Class A shares to FAT Brands shareholders, bringing Twin Hospitality public.

A Premium Sports Bar Leader. Twin Hospitality currently operates approximately 115 Twin Peaks locations, consisting of 35 Company-owned and 80 franchised units. Twin Peaks offers a differentiated sports bar experience, from the lodge experience, to its signature 28-degree draft beer, a made-from-scratch menu, always-on wall-to-wall TVs, to the Twin Peaks Ambassadors, every customer receives an experience differentiated from the competition.

Get the Full Report

Noble Capital Markets Research Report Thursday, October 16, 2025

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Highlights from the Noble Emerging Growth Virtual Conference
Comstock (LODE)/MARKET PERFORM – Strategic Acquisition Expands Nevada Mining Footprint
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Hitting All the Right Notes

Alliance Resource Partners (ARLP/$24.6 | Price Target: $32)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Highlights from the Noble Emerging Growth Virtual Conference
Rating: OUTPERFORM

Noble virtual conference. Alliance recently participated in Noble Capital Markets’ Emerging Growth Virtual Conference. The fundamental outlook for ARLP’s coal operations and oil and gas royalty business, the two largest drivers of cash flow, remains favorable. The coal and electric power generation industries are expected to benefit from Trump Administration policies that seek to assure affordable, reliable, and secure energy sources to meet growing demand for electricity. Through 2Q 2025, Alliance has invested $758 million in its oil and gas royalty business that has generated cumulative segment adjusted EBITDA of $622 million. While they have grown the oil and gas royalty business without the use of leverage, they do have the ability to employ leverage for larger acquisitions. A link to the presentation is here.

Capital allocation. Management takes a long-term view when making capital allocation decisions, with balance sheet strength being the highest priority. The next priority is investing in its coal business to ensure it remains an efficient and low-cost producer. The third priority is reinvesting the cash flow generated by the oil and gas business to make accretive acquisitions. Lastly, the company intends to return capital to shareholders, including attractive cash distribution payments, while ensuring flexibility to fund growth opportunities.

Get the Full Report

Comstock (LODE/$4.23)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strategic Acquisition Expands Nevada Mining Footprint
Rating: MARKET PERFORM

Acquisition of Haywood Quarry. Comstock completed the acquisition of the Haywood Quarry industrial and mineral properties from Decommissioning Services LLC. The 190-acre property, located in Lyon County, Nevada, includes available power, water, and direct access to U.S. Highway 50. The site historically hosted gold mining and aggregate operations and is strategically contiguous to Comstock’s flagship Dayton gold and silver resource.

Transaction terms. Comstock acquired the property for a total of $2.2 million in cash and stock from Decommissioning Services LLC. The transaction provides Comstock with full ownership and control of the Haywood industrial and mineral properties, integrating them into its broader Lyon County mineral estate. The purchase also enhances Comstock’s strategic flexibility in advancing mine planning, resource development, and reclamation initiatives at the Dayton complex.

Get the Full Report

Nicola Mining Inc. (HUSIF/$0.77 | Price Target: $1.2)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hitting All the Right Notes
Rating: OUTPERFORM

Treasure Mountain exploration. Nicola Mining Inc. (OTCQB: HUSIF, TSXV: NIM) provided an update on its plan for 2026 exploration drilling at the Treasure Mountain Silver Project. The area of exploration interest is northwest of the currently suspended mine and consists of several northeast to southwest trending and steeply dipping sulphide-rich veins. Results from previous exploration work confirmed the presence of vein-hosted silver, copper, lead, zinc, and gold, providing support for initial diamond drilling to establish the width of the trend and mineralization at depth.

Recent gold sales. Talisker Resources (OTCQB: TSKFF, TSX: TSK) has an agreement to process run-of-mine material from its Mustang Mine at Nicola’s Merritt Mill. For the quarter ending on September 30, a total of 1,569 ounces of gold were produced from Talisker’s Mustang Mine. Nicola receives a share of the gross profit from milling ore sourced from Talisker Resources Ltd. Blue Lagoon Resources Inc. (OTCQB: BLAGF, CSE: BLLG) recently announced an amended mining and milling partnership agreement with Nicola Mining, extending the partnership to a 10-year term. The agreement secures a long-term processing solution for mineralized material from Blue Lagoon’s high-grade Dome Mountain Gold Project.

Get the Full Report

Noble Capital Markets Research Report Tuesday, October 14, 2025

Companies contained in today’s report:

Alliance Entertainment Holding (AENT)/OUTPERFORM – Noble Virtual Conference Highlights
EuroDry (EDRY)/MARKET PERFORM – Recovering Rates and Greater Liquidity Enhance Outlook
NeuroSense Therapeutics Ltd. (NRSN)/OUTPERFORM – Novel Therapy for ALS and Neurodegenerative Diseases
ONE Group Hospitality (STKS)/OUTPERFORM – Randian Adds Some Detail
Saga Communications (SGA)/OUTPERFORM – Highlights From Noble’s Virtual Emerging Growth Conference
Sky Harbour Group (SKYH)/OUTPERFORM – Noble Virtual Conference Highlights
SKYX Platforms (SKYX)/OUTPERFORM – Noble Virtual Conference Highlights
Snail (SNAL)/OUTPERFORM – Highlights From Noble’s Virtual Conference
Superior Group of Companies (SGC)/OUTPERFORM – Highlights from Noble’s Virtual Conference
Townsquare Media (TSQ)/OUTPERFORM – Highlights From Noble’s Virtual Conference
Vince Holding Corp. (VNCE)/OUTPERFORM – Highlights From Noble’s Virtual Conference

Alliance Entertainment Holding (AENT/$6.42 | Price Target: $11)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Management appeared confident. Bruce Ogilvie, Executive Chairman, and Jeffrey Walker, CEO, presented at Noble’s October 8th & 9th Virtual Emerging Growth Conference. This report highlights the company’s presentation and fireside Q&A chat, which provided a sanguine outlook for improved margins into fiscal 2026. Investors may listen to the company’s presentation here

Favorable margin expansion outlook. Operating margins are expected to expand in fiscal 2026, supported by a full year of the company’s high margin licensing deal with Paramount and development of its Handmade by Robots collectible line. In addition, management anticipates further operating efficiencies. 

Get the Full Report

EuroDry (EDRY/$12.58)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Recovering Rates and Greater Liquidity Enhance Outlook
Rating: MARKET PERFORM

Vessel sale enhances liquidity. EuroDry recently announced an agreement to sell the M/V Eirini P. to a third party for approximately $8.5 million, with the transaction expected to close in October 2025. The sale is projected to generate a gain of approximately $0.6 million, or roughly $0.21 per share. The proceeds will enhance near-term liquidity and strengthen EuroDry’s flexibility to pursue selective investments in more efficient vessels.

Market environment improving. The dry-bulk market has shown signs of recovery as charter rates have recently rebounded from multi-year lows. The improvement reflects strengthening market sentiment, supported by limited fleet growth and rising expectations for Chinese demand. A historically low orderbook and modest fleet expansion provide a constructive foundation for rate stabilization heading into 2026.

Get the Full Report

NeuroSense Therapeutics Ltd. (NRSN/$1.22 | Price Target: $9)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Novel Therapy for ALS and Neurodegenerative Diseases
Rating: OUTPERFORM

We Are Initiating Coverage of NeuroSense With An Outperform Rating. NeuroSense Therapeutics is developing therapies for degenerative neurological conditions. The lead product, PrimeC, has completed two Phase 2 trials for ALS (Amyotrophic Lateral Sclerosis) and has a Phase 3 trial planned for early 2026. Initial results from Phase 2 in Alzheimer’s disease has shown promising data. Our price target is $9 per share.

The Lead Indication For PrimeC Is in ALS. PrimeC is a novel formulation containing a combination of celecoxib and ciprofloxacin. These two drugs have been used separately for anti-inflammatory and anti-antimicrobial indications. After new data showed that each drug can affect pathways of degenerative disease, scientists at NeuroSense tested the two drugs together in models of ALS and found a synergistic effect. Two Phase 2 studies showed benefits on survival, disease progression, and biomarkers of ALS activity.

Get the Full Report

ONE Group Hospitality (STKS/$2.56 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Randian Adds Some Detail
Rating: OUTPERFORM

Additional Detail. Randian Capital added another post on the social media platform X, providing additional details to its proposed turnaround plan for ONE Group Hospitality. Reportedly, the latest Randian X post was in response to STKS CEO Manny Hilario and CFO Nicole Thaung stating they had not engaged with Randian and were unaware if the firm held shares. The pair reiterated that ONE Group had no changes to guidance or plans for capital deployment being made.

The Driver. As we noted in our September 29th note, Randian believes there is tangible, underutilized value in this franchise—especially in Benihana, a legendary brand with global recognition and untapped potential. However, poor capital allocation, slipping operational execution, and marketing that is failing to drive engagement have resulted in a 60% decline in the share price since the 2024 Benihana acquisition, according to Randian.

Get the Full Report

Saga Communications (SGA/$12.6 | Price Target: $18)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From Noble’s Virtual Emerging Growth Conference
Rating: OUTPERFORM

A blended growth opportunity. This report highlights a fireside chat with Christopher Forgy, CEO & President, and Samuel Bush, CFO, at Noble’s Virtual Emerging Growth Conference on October 8th & 9th. Management highlighted its attractive growth opportunities from its “blended” advertising strategy. The full presentation may be viewed here. 

Blended advertising strategy. Saga’s approach integrates radio (“wanted”), search (“found”), and display (“chosen”) to capture the full consumer journey. Management targets disrupting 5% of local digital ad spend to double annual gross revenue, focusing on 27 small-to-medium-sized markets where the company has trusted community relationships.

Get the Full Report

Sky Harbour Group (SKYH/$10.07 | Price Target: $23)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble virtual conference highlights. Tal Keinan (CEO) and Francisco Gonzalez (CFO) of Sky Harbour Group (NYSE: SKYH) presented at Noble’s Emerging Growth Virtual Conference on October 8–9, 2025. Management highlighted continued lease-up at Phoenix, Dallas, and Denver, steady pre-leasing at Dulles (IAD) and Bradley (BDL), and progress on capital efficiency. A rebroadcast can be found here.

Leasing and pipeline on pace. Operations at Phoenix, Dallas, and Denver are leasing at a good clip, and the company has secured one pre-lease tenant at both IAD and BDL ahead of construction. Sky Harbour now holds long-term ground leases at 18 airports (nine operating, nine in development) and reaffirmed plans to add five more by year-end, bringing the total to 23.

Get the Full Report

SKYX Platforms (SKYX/$1.26 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Highlights from Noble’s Emerging Growth Virtual Conference. Lenny Sokolow, CEO of SKYX Platforms (NASDAQ: SKYX), presented at Noble’s Virtual Conference on October 8–9, 2025. He discussed growing developer adoption, the upcoming Smart Ceiling Heater / Fan launch, progress toward mandatory code standardization, and reaffirmed expectations for adj. EBITDA inflection in Q4. A rebroadcast can be found here.

Developer partnerships gaining momentum. SKYX continues to expand across the builder channel with projects from Landmark Companies (278-unit Austin apartments), Forte Developments (luxury towers in Miami, Clearwater Beach, and Jupiter), Cavco Homes (premium prefabricated models), and the $3 billion Miami Urban Smart City. These initiatives represent large-scale unit potential and underscore accelerating adoption among professional developers.

Get the Full Report

Snail (SNAL/$1.04 | Price Target: $3.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

Prospects for Stablecoin. This report highlights key takeaways from the company’s presentation at Noble’s Virtual Emerging Growth Conference on October 8th & 9th. Heidy Chow, CFO, and Peter Lin, FP&A outlined the key growth attributes for the company, including its emerging interest in developing a stablecoin. The full presentation may be found here. 

Solid 2024 Performance and Franchise Resilience. Snail delivered a strong year, with FY2024 revenue reaching $85 million, supported by its enduring ARK franchise, which has accumulated over 90 million players and 4.1 billion total playtime hours since launch.

Get the Full Report

Superior Group of Companies (SGC/$10.07 | Price Target: $16)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights from Noble’s Virtual Conference
Rating: OUTPERFORM

Plowing through the trade fog. Michael Benstock, Chairman and CEO, and Michael Koempel, President and CFO, presented at Noble’s October 8th & 9th Virtual Emerging Growth Conference. This report highlights the company’s fireside Q&A chat, which provided a constructive revenue and earnings growth outlook in spite of trade policy turmoil. Investors may listen to the company’s presentation here. 

Diversified operations. The company operates in three segments, healthcare apparel, branded products, and contact centers. Diversification across these three segments provides both growth potential and resilience against macroeconomic uncertainty, including tariffs and political volatility.

Get the Full Report

Townsquare Media (TSQ/$6.09 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

A differentiated digital company. Bill Wilson, CEO, Stuart, Rosenstein, CFO, and Claire Yenicay, Executive Vice President, participated in a fireside chat at Noble’s Virtual Emerging Growth Conference on October 8th & 9th. The discussion focused on the company’s differentiated digital growth opportunities and compelling total return potential. This report provides some of the highlights from the discussion, but the full discussion may be viewed here.  

Townsquare Interactive turning towards growth. Townsquare Interactive provides subscription-based digital marketing solutions for SMBs at ~$300/month, offering website management, CRM, email/text marketing, and payment integration. After temporary disruption in 2023–2024 due to a service model overhaul and return-to-office mandate, 2025 is returning to strong profit growth (~$3 million), with revenue growth expected to resume in 2026.

Get the Full Report

Vince Holding Corp. (VNCE/$2.66 | Price Target: $4.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From Noble’s Virtual Conference
Rating: OUTPERFORM

Transformational progress. Brendan Hoffman, CEO, Yuji Okumura, CFO, and Akiko Okuma, Chief Administrative Officer, discussed the significant transformation of the company toward revenue and cash flow growth and profitability at Noble’s Virtual Emerging Growth Conference on October 8th & 9th. Highlights from the fireside chat are featured in this report, and the full discussion is available here

Minimizing the China impact. The company significantly reduced sourcing concentration from roughly 60% of production in China to approximately 25% today, offsetting the impact of tariff rates as high as 158%. Management noted that long-standing manufacturing partners in China have established sister facilities in other Asian countries, helping preserve quality standards while lowering exposure risk.

Get the Full Report

Noble Capital Markets Research Report Monday, October 13, 2025

Companies contained in today’s report:

CoreCivic, Inc. (CXW)/OUTPERFORM – Noble Virtual Conference Highlights
FAT Brands (FAT)/OUTPERFORM – Some Legal Resolution
NN (NNBR)/OUTPERFORM – Noble Virtual Conference Highlights
Resources Connection (RGP)/OUTPERFORM – Post Call Commentary

CoreCivic, Inc. (CXW/$17.99 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. CoreCivic CFO David Garfinkle and Managing Director of Investor Relations Jeb Bachmann presented at the Noble Virtual Conference. Highlights included increased demand, long-term trends, and return of capital. A rebroadcast is available at https://www.channelchek.com/videos/corecivic-cxw-noble-capital-markets-virtual-conference-replay-october-2025.

Market Share. CoreCivic remains the largest non-government owner of correctional and detention real estate in the U.S., owning approximately 57% of all privately owned correctional and detention capacity. The Company manages approximately 41% of all privately managed correctional and detention capacity.

Get the Full Report

FAT Brands (FAT/$1.98 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Legal Resolution
Rating: OUTPERFORM

Legal Resolution. In an 8-K filing, FAT Brands disclosed that the Company and certain current and former directors and officers have reached a settlement agreement with stockholders of the Company to resolve two lawsuits known as Harris I and Harris II. The Derivative Actions were filed in June 2021, relating to the Company’s December 2020 merger with Fog Cutter Capital Group, and in March 2022, relating to the Company’s June 2021 recapitalization.

Details. Under the terms of the settlement agreement, the Company’s Board of Directors agreed to adopt and implement certain corporate governance modifications. In addition, the Company’s insurers will pay to the Company $10 million, from which fees and expenses of plaintiffs’ counsel will be deducted, and Fog Cutter Holdings LLC will contribute 200,000 Class A shares of Twin Hospitality Group Inc. to the Company.


Get the Full Report

NN (NNBR/$1.82 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. NN CEO Harold Bevis, CFO Chris Bohnert, and COO Tim French presented at the Noble Virtual Conference. Highlights included improving end markets outlook, an on track new business win program, and a focus on de-leveraging. A rebroadcast is available at https://www.channelchek.com/videos/nn-inc-nnbr-noble-capital-markets-virtual-conference-replay-october-2025.

Phase 2. NN is entering Phase 2 of its transformation program. Phase 1 structurally rebuilt NN’s operating performance and efficiency through fixing unprofitable areas, improving margins, and entering new markets. Phase 2 is a growth and de-leverage focus, implementing new business programs, expanding the TAM, and addressing the preferred stock.

Get the Full Report

Resources Connection (RGP/$4.54 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Post Call Commentary
Rating: OUTPERFORM

Some Positives. The Company continues on its transformation path and is seeing encouraging signs, in our opinion. For example, the Company saw a return to growth in revenue for both the Europe & Asia- Pac segment and the Outsourced Services segment, with 5% and 4% growth over the prior year quarter. Revenue from the top 10 clients also grew year-over-year, and the enterprise-wide average bill rate increased to $120 on a constant currency basis, up from $118 a year ago.

Ongoing Cost Focus. The other side of the transformation plan is a focus on cost control. RGP continues to make good progress on its SG&A, as reflected in the quarter’s numbers. Post quarter, on September 30, 2025, in the face of continued end market sluggishness, RGP commenced a global reduction in its management and administrative workforce intended to enhance efficiencies through reduced costs and streamlined operations. Management expects approximately $6 million to $8 million of annual cost savings associated with this effort.

Get the Full Report

Noble Capital Markets Research Report Friday, October 10, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – A Multi-Year Growth Story

AZZ (AZZ/$100.75 | Price Target: $120)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
A Multi-Year Growth Story
Rating: OUTPERFORM

FY 2026 second-quarter results. AZZ reported adjusted net income of $46.9 million, or $1.55 per share, compared to $41.3 million, or $1.37 per share, during the prior year period. We projected adjusted net income of $46.7 million, or $1.54 per share. Compared to the second quarter of FY 2025, total sales increased 2.0% to $417.3 million. We had projected sales of $428.3 million. Gross margin of $101.3 million was modestly below our estimate of $104.7 million. Adjusted EBITDA declined modestly to $88.7 million compared to $91.9 million during the prior year period and our estimate of $93.4 million. Adjusted EBITDA margin as a percentage of sales declined to 21.3% compared to 22.5% during the prior year quarter.

Updating estimates. We have lowered our FY 2026 revenue, adjusted EBITDA, and adjusted EPS estimates to $1.642 billion, $369.2 million, and $5.98 per share, respectively, from $1.660 billion, $374.9 million, and $6.00 per share. Our revised forecasts reflect second-quarter results and more moderate sales growth in the second half of the year. Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates could prove conservative if AZZ is successful in consummating acquisitions, which we do not reflect in our estimates until announced.

Get the Full Report

Noble Capital Markets Research Report Thursday, October 9, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Staying Focused on the Big Picture
Bit Digital (BTBT)/OUTPERFORM – Monthly Ethereum Metrics
Resources Connection (RGP)/OUTPERFORM – First Look at 1Q26

AZZ (AZZ/$105.94 | Price Target: $125)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Staying Focused on the Big Picture
Rating: OUTPERFORM

FY 2026 second-quarter financial results. AZZ reported adjusted net income of $46.9 million, or $1.55 per share, compared to $41.3 million, or $1.37 per share, during the prior year period. We had forecast adjusted net income of $46.7 million, or $1.54 per share. Compared to the second quarter of FY 2025, total sales increased 2.0% to $417.3 million. We had projected sales of $428.3 million. Gross margin of $101.3 million was modestly below our estimate of $104.7 million. Sales and gross margins trailed our expectations for both segments. However, operating income of $68.5 million exceeded our estimate of $66.1 million due to lower selling, general, and administrative expenses. Adjusted EBITDA declined modestly to $88.7 million compared to $91.9 million during the prior year period and our estimate of $93.4 million. Adjusted EBITDA margin as a percentage of sales declined to 21.3% compared to 22.5% during the second quarter of FY 2025.

Results were mixed. While Metal Coatings sales were up 10.8% compared to the prior year quarter, Precoat Metals sales were down 4.3%. Metal Coatings delivered higher sales due to increased volume driven by infrastructure-related projects in several end markets. Precoat Metals experienced lower sales due to weaker end markets, including building construction, HVAC, and appliance.

Get the Full Report

Bit Digital (BTBT/$4.04 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Monthly Ethereum Metrics
Rating: OUTPERFORM

Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of September 2025. As of September 30, 2025, the Company held approximately 121,187 ETH, versus 121,252 ETH at the end of August. Included in the ETH holdings were approximately 15,075 ETH and ETH-equivalents held in an externally managed fund, and approximately 5,142 ETH presented on an as-converted basis from LsETH using the Coinbase conversion rate as of 9/30/25. The Company’s total staked ETH was approximately 99,936 as of September 30th.

Yield and Value. Staking operations generated approximately 291 ETH in rewards during September, representing an annualized yield of approximately 3.37%. Based on a closing ETH price of $4,145.99, as of September 30, 2025, the market value of the Company’s ETH holdings was approximately $506.6 million.

Get the Full Report

Resources Connection (RGP/$4.95 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
First Look at 1Q26
Rating: OUTPERFORM

A Beat. Resources Connection reported first quarter revenue, gross margin, and SG&A expenses better than expected, although the top line continued to decline y-o-y, as expected. RGP is engaging with clients on more consulting opportunities, which have higher bill rates, larger deal size, and often create more extension and cross selling. However, the macro environment remains unpredictable, which makes clients hesitant to begin new projects.

Details. 1Q26 revenue came in at $120.2 million, down from $136.9 million in 1Q25, but above the $120 million high-end of management’s guidance. Gross margin came in at 39.5%, a significant y-o-y improvement from 36.5% in 1Q25 and above the 36-37% guidance range. SG&A expense of $47.9 million improved from $48.9 million in 1Q25. RGP recorded a GAAP net loss of $2.4 million, or $0.07/sh, compared to a $5.7 million, or $0.17/sh, net loss, in 1Q25. Adjusted EPS was $0.03/sh versus breakeven last year. 

Get the Full Report

Noble Capital Markets Research Report Monday, October 6, 2025

Companies contained in today’s report:

Alliance Entertainment Holding (AENT)/OUTPERFORM – Delivering Music To Our Ears: Cash Flow And Earnings Growth
SKYX Platforms (SKYX)/OUTPERFORM – Strengthening Position Among Residential Developers
Xcel Brands (XELB)/OUTPERFORM – Exiting A Successful Run

Alliance Entertainment Holding (AENT/$6.73 | Price Target: $11)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Delivering Music To Our Ears: Cash Flow And Earnings Growth
Rating: OUTPERFORM

Initiating coverage with Outperform rating. Alliance Entertainment is a leading distributor of physical products, including vinyl records, music CDs, Blu-ray and 4K Movies, Video Games and Electronics, and Collectibles. While some of its business lines are mature, there are attractive growth opportunities in developing revenue streams that carry higher margins. As such, we believe that the company is on the cusp of generating significant cash flow and earnings growth.

Expanding margin outlook. In spite of anticipated modest revenue growth of 2.4% in fiscal 2026, we anticipate a nearly 140 basis point improvement in adj. EBITDA margins in fiscal 2026, given our expectation of higher margin, developing revenue streams and the company’s focus on efficiencies. We expect an acceleration in revenue in fiscal 2027 to 3.1% with another 60 basis point improvement in margins. 

Get the Full Report

SKYX Platforms (SKYX/$1.13 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Strengthening Position Among Residential Developers
Rating: OUTPERFORM

Landmark partnership expands builder channel. SKYX announced it will supply more than 10,000 smart plug-and-play lighting and safety products to a 278-apartment project in Austin, Texas led by Landmark Companies. We believe this marks another important step in the company’s efforts to penetrate the builder channel, signaling traction with traditional residential developers.

Potential for broader builder relationships. By establishing a relationship with a large developer like Landmark, SKYX positions itself for additional project opportunities if early deployments prove successful. This deal highlights the potential for SKYX to extend its platform into the broader residential developer market, with initial supply expected to begin as early as within the next quarter or two.

Get the Full Report

Xcel Brands (XELB/$2.38 | Price Target: $7)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Exiting A Successful Run
Rating: OUTPERFORM

Exits its Mizrahi interest. The company transferred its remaining 17.5% interest in Isaac Mizrahi to IM Topco, effectively exiting its interest in the brand. The exit of the Mizrahi relationship with Xcel caps a storied and successful run with the company since 2011. Under Xcel, Mizrahi expanded its categories and collections on QVC and into such retailers as Bloomingdale’s and Nordstrom.  

Financial upside. Xcel has a participation right should IM Topco sell the company above $46.0 million, coincidentally, the price that Xcel sold its 60% interest. Xcel would receive 15% of the net consideration in excess of the $46 million. In addition, we believe that the company will benefit from the absent of costs related to the brand, particularly employee costs. 

Get the Full Report

Noble Capital Markets Research Report Friday, October 3, 2025

Companies contained in today’s report:

Bitcoin Depot (BTM)/OUTPERFORM – Favorable Preliminary Results and Tuck-in Acquisition

Bitcoin Depot (BTM/$3.83 | Price Target: $9)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Favorable Preliminary Results and Tuck-in Acquisition
Rating: OUTPERFORM

Strong preliminary results. Bitcoin Depot announced preliminary Q3 results of approximately $160M in revenue (+18% Y/Y) and roughly 50% growth in adj. EBITDA versus the prior year. Both topline and profitability are tracking well ahead of management’s prior Q2 guidance of high-single-digit revenue and 20–30% adj. EBITDA growth.

Beating expectations. In light of these results, the company is expected to exceed our Q3 forecast of $146.5M in revenue and $11.0M in adj. EBITDA. Preliminary figures imply approximately $13.8M in adj. EBITDA, meaning profitability should surpass our expectations by nearly 25%.

Get the Full Report

Noble Capital Markets Research Report Thursday, October 2, 2025

Companies contained in today’s report:

Century Lithium Corp. (CYDVF)/OUTPERFORM – Progress on the Permitting Front
CoreCivic, Inc. (CXW)/OUTPERFORM – An Award for Diamondback
Seanergy Maritime (SHIP)/OUTPERFORM – Strategic Vessel Sale and Improving Capesize Fundamentals
V2X (VVX)/OUTPERFORM – Some More Awards

Century Lithium Corp. (CYDVF/$0.29 | Price Target: $2.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Progress on the Permitting Front
Rating: OUTPERFORM

Moving through the permitting process. Century has completed all required environmental baseline studies to begin Angel Island’s National Environmental Policy Act (NEPA) permitting process, which is expected to take up to two years before reaching a record of decision. The studies will be used by the Bureau of Land Management (BLM) to support the company’s upcoming Plan of Operations submission and subsequent NEPA analysis. 

FAST-41 designation. In August 2025, Angel Island was formally designated as a FAST-41 Transparency project under a federal initiative designed to improve the transparency, coordination, and timeliness of the federal environmental review and permitting process. The designation reflects Angel Island’s strategic importance in supporting the U.S. critical minerals supply chain. We think the Angel Island project is well-positioned for a timely progression through the permitting process.

Get the Full Report

CoreCivic, Inc. (CXW/$20.55 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
An Award for Diamondback
Rating: OUTPERFORM

Diamondback. Yesterday, CoreCivic announced it was awarded a new contract under an Intergovernmental Services Agreement between the Oklahoma Department of Corrections and U.S. Immigration and Customs Enforcement (“ICE”) to resume operations at the Company’s 2,160-bed Diamondback Correctional Facility, a facility that has been idle since 2010.

Details. The new contract commenced on September 30, 2025, for a term of five years and may be extended through bilateral modification. The agreement provides for a fixed monthly payment plus an incremental per diem payment based on detainee populations. Total annual revenue once the facility is fully activated is expected to be approximately $100 million. The facility should begin receiving detainees in the first quarter of 2026, with the full ramp estimated to be complete in the second quarter of 2026.

Get the Full Report

Seanergy Maritime (SHIP/$8.58 | Price Target: $11)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strategic Vessel Sale and Improving Capesize Fundamentals
Rating: OUTPERFORM

Sale of M/V Geniuship. Seanergy announced the sale of the M/V Geniuship, a 170,057 dwt Capesize vessel, for approximately $21.6 million, generating net cash proceeds of $12.0 million and a profit of about $2.5 million. The sale was timed to take advantage of improved vessel valuations while avoiding the costs of the vessel’s scheduled dry-docking. The transaction enhances liquidity, improves near-term earnings, and aligns with the company’s ongoing fleet renewal strategy.

Capesize market gains momentum. The Capesize market has strengthened in recent months, supported by iron ore and bauxite projects in the Atlantic basin and West Africa, while volatility due to tariffs has moderated. The orderbook remains limited, with shipyard slots not available until 2029. Rising vessel values, together with higher construction costs, have further restricted orders. Overall, we expect market conditions to remain favorable, with 2026 showing improvement over 2025.

Get the Full Report

V2X (VVX/$58.08 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some More Awards
Rating: OUTPERFORM

Awards. V2X has been the recipient of new awards, including one focused on extending the life-cycle of existing platforms and another driving connectivity and communications. In total, the three new awards total over $580 million of contract value, assuming all funds are spent. We view the recent wins as further confirmation of V2X’s ability to provide full mission lifecycle solutions.

Center Display Units. V2X’s Vertex Modernization and Sustainment unit was awarded by the Air Force a five-year ID/IQ contract with a single five-year option (10 years total) with a contract ceiling of $425 million for center display units (CDU), according to the Department of War’s daily contract awards. V2X will supply the Air Force with the following hardware during this period: CDU full kits, CDU line replaceable units, CDU shop replaceable units, and various other support hardware as required.

Get the Full Report

Noble Capital Markets Research Report Wednesday, October 1, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – A Convertible Note Offering
The GEO Group (GEO)/OUTPERFORM – Retains ISAP Contract

Bit Digital (BTBT/$3 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Convertible Note Offering
Rating: OUTPERFORM

An Offering. Bit Digital is offering $135 million of convertible notes. The deal is upsized from an original $100 million. Net proceeds from the offering will be used primarily to purchase Ethereum, and may be used for general corporate purposes, including potential investments, acquisitions, and other business opportunities. The capital raise continues management’s goal of becoming a major Ethereum treasury company, in our view.

Details. The Notes will be senior, unsecured obligations of the Company and will accrue interest at a rate of 4.00% per year, payable semiannually in arrears. The Notes will mature on October 1, 2030. The initial conversion rate will be 240.3846 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of $4.16 per ordinary share and represents a conversion premium of 30% above the last reported sale price of the ordinary shares on September 29, 2025, which was $3.20).

Get the Full Report

The GEO Group (GEO/$20.49 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Retains ISAP Contract
Rating: OUTPERFORM

ISAP Award. As we had expected, The GEO Group has retained the Intensive Supervision Appearance Program (“ISAP”) contract. U.S. Immigration and Customs Enforcement (“ICE”) awarded the contract to GEO’s BI subsidiary for the continued provision of electronic monitoring, case management, and supervision services. It is a two-year contract, which will have an initial term of one year, effective  October 1, 2025, with an additional one-year option period.

Long-time Services Provider. BI has provided technology solutions, holistic case management, supervision, monitoring, and compliance services under the ISAP contract for over 21 years and has achieved high levels of compliance using a wide range of technologies and case management services over that time.

Get the Full Report

Noble Capital Markets Research Report Tuesday, September 30, 2025

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – U.S. Coal as a Strategic and Competitive Advantage
CoreCivic, Inc. (CXW)/OUTPERFORM – Letter Contracts to Contract Awards
ONE Group Hospitality (STKS)/OUTPERFORM – Activist Investor Sees $10+ Stock in 12-18 Months

Alliance Resource Partners (ARLP/$25.02 | Price Target: $32)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
U.S. Coal as a Strategic and Competitive Advantage
Rating: OUTPERFORM

Investments to reinvigorate the U.S. coal industry.  The U.S. Department of Energy announced a $625 million program to expand and reinvigorate the U.S. coal industry. This includes $350 million to recommission or modernize coal power units, $175 million for coal power projects directly benefiting rural communities, $50 million to support advanced wastewater management systems to enable coal plants to extend their service life and reduce operational costs, $25 million for dual-firing retrofits, and $25 million for development and testing of natural gas cofiring systems.

Expanded coal leasing on federal lands. Moreover, the U.S. Department of the Interior announced it is making up to 13.1 million acres of federal land available for coal leasing and streamlining approvals for projects. The Department is accelerating efforts to fast-track projects that can recover strategic minerals from mine waste and abandoned sites. The One Big Beautiful Bill, passed on July 4, established lower coal leasing royalty rates of not more than 7% for both surface and underground mines for the period July 4, 2025, to September 30, 2034.

Get the Full Report

CoreCivic, Inc. (CXW/$21.54 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Letter Contracts to Contract Awards
Rating: OUTPERFORM

Contract Awards. As anticipated, U.S. Immigration and Customs Enforcement (ICE) awarded CoreCivic two new contracts, which, once fully activated, would generate total annual revenue of approximately $200 million. The two facilities, California City and Midwest Regional, had been operating under Letter Contracts with ICE, which enable CoreCivic to begin operations at a facility while negotiating a longer-term contract. Both facilities were idle at the beginning of the year.

California City. CoreCivic has been preparing to accept detainees at the 2,560-bed California City facility since April 1, 2025. The Company began receiving detainees at the facility on August 27, 2025. Management currently expects the activation to be complete in 1Q26, achieving a normalized run-rate in 2Q26. Total annual revenue, once the activation is complete, is expected to be approximately $130 million. The new contract expires in August 2027.

Get the Full Report

ONE Group Hospitality (STKS/$3.12 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Activist Investor Sees $10+ Stock in 12-18 Months
Rating: OUTPERFORM

Activist Investor. Randian Capital, part of the “retail activist” group behind the sharp rise in Opendoor Technologies (OPEN) stock from less than a $1 mid-summer to around $8.20 today, released on social media platform X a turnaround proposal for The ONE Group. In a nutshell, the plan consists of Refocus the Portfolio, Revitalize the Brand, Strengthen Operations, and Capital Discipline & Growth. Radian sees a path to a $10+ stock over the next 12-18 months. STKS shares rose over 26% yesterday on the news.

Refocus & Revitalize. Randian calls for ONE Group to refocus solely on its Benihana concept, selling off all other concepts. The activist investor believes the STK concept alone could be worth more than the current market cap. Randian suggests rebranding as Benihana Group and changing the stock symbol. Revitalization by elevating the dining experience and engaging with cultural icons, among other changes.

Get the Full Report

Noble Capital Markets Research Report Friday, September 26, 2025

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Heightened Risk in Ecuador
AZZ (AZZ)/OUTPERFORM – Revising Estimates; Growth Outlook Remains Favorable
Steelcase (SCS)/MARKET PERFORM – A Better Than Expected 2Q26

Aurania Resources (AUIAF/$0.1 | Price Target: $0.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Heightened Risk in Ecuador
Rating: OUTPERFORM

Second quarter financial results. As an exploration company, Aurania does not generate revenue and has expenses to advance its projects. During the second quarter of 2025, the company generated a net loss of C$1,610,843 or C$0.01 per share. We had projected a loss of C$1,432,419 or C$0.01 per share. The variance to our estimate was mostly due to higher exploration expenditures, along with higher stock-based compensation. We project a full-year 2025 net loss of C$11.1 million, or C$(0.10) per share, compared to our prior loss estimate of C$10.5 million, or C$(0.09) per share.

Mining service fee. Ecuador recently implemented a new mining service fee on the resource sector (refer to our note dated July 29, 2025). The Ecuadorian Control and Regulation Agency (ARCOM) requested payment from Aurania of US$2,012,618 by July 31, 2025, representing one month of the total annual fee of US$24,151,420. While the penalty for non-payment is unclear, we think Aurania is withholding payment until it becomes clear whether TASA will stand in its current form due to multiple constitutional challenges.

Get the Full Report

AZZ (AZZ/$110.64 | Price Target: $125)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Revising Estimates; Growth Outlook Remains Favorable
Rating: OUTPERFORM

Updating estimates. We are lowering our second-quarter revenue, adjusted EBITDA, and adjusted EPS estimates to $428.3 million, $93.4 million, and $1.54, respectively, from $433.5 million, $101.1 million, and $1.59. While we have increased our revenue estimate for the Metal Coatings segment, we lowered expectations for Precoat Metals due to anticipated weakness in building construction. Our FY 2026 revenue, adjusted EBITDA, and adjusted EPS estimates are $1.660 billion, $374.9 million, and $6.00, respectively, compared to our prior estimates of $1.680 billion, $388.3 million, and $6.00. Our revised estimates reflect lower interest expense, along with modestly lower depreciation and amortization expense.

Organic and acquired growth. AZZ’s three-year goals include generating sales of two billion dollars or more in fiscal year 2028, compared to its trailing twelve-month sales of $1.6 billion. Organic growth is expected to exceed GDP growth, and AZZ is targeting acquisitions that strengthen both of its business segments. While we do not forecast sales of $2.0 billion until 2031, our model does not reflect acquisitions until they are announced.

Get the Full Report

Steelcase (SCS/$16.7)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Better Than Expected 2Q26
Rating: MARKET PERFORM

2Q26. In what is likely the Company’s final quarterly report as a public company, Steelcase reported better than expected results. Results benefitted from continued strengthening of demand from large corporate customers and International growth driven by India, China, and the United Kingdom. Improved International volume drove a $5 million reduction in y-o-y adjusted operating loss in the International segment. These were Steelcase’s highest quarterly results over the past five years.

Financials. Revenue of $897.1 million rose 4.8% y-o-y and exceeded the $890 million high end of management’s guidance. We were at $875 million. Gross margin of 34.4% was flat y-o-y and exceeded the 33.5% high end of guidance. Adjusted EBITDA totaled $99.6 million, or 11.1% of revenue, up from $89.5 million and 10.5% in 2Q25. Adjusted EPS was $0.45, versus $0.39 last year and above management’s $0.40 high end guide. We were at $0.36.

Get the Full Report

Noble Capital Markets Research Report Wednesday, September 24, 2025

Companies contained in today’s report:

SelectQuote (SLQT)/OUTPERFORM – Reaches Milestone in Helping Medicare-Eligible Seniors

SelectQuote (SLQT/$2.08 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Reaches Milestone in Helping Medicare-Eligible Seniors
Rating: OUTPERFORM

Milestone in Findhelp partnership. SelectQuote  announced that it has referred more than 200,000 low-income seniors to Findhelp, with nearly 50,000 of those individuals accessing free or reduced-cost services. The milestone demonstrates SelectQuote’s role in addressing the needs of Medicare-eligible consumers.

Partnership connects consumers to critical support. Findhelp is a closed-loop referral management software platform that connects individuals with community resources such as food, housing, transportation, and financial aid. SelectQuote has partnered with Findhelp for several years, directing seniors to assistance programs. The initiative does not generate revenue, but it extends SelectQuote’s Medicare distribution model by providing tangible value to consumers.

Get the Full Report

Noble Capital Markets Research Report Tuesday, September 23, 2025

Companies contained in today’s report:

The ODP Corporation (ODP)/MARKET PERFORM – To Be Acquired for $28/sh

The ODP Corporation (ODP/$27.68)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
To Be Acquired for $28/sh
Rating: MARKET PERFORM

An Acquisition. Yesterday morning, The ODP Corporation announced it entered into a definitive agreement to be acquired by an affiliate of Atlas Holdings for $28/sh. The purchase price represents a premium of 34% to Friday’s closing price. ODP’s Board is supporting the transaction, which is expected to close by the end of 2025.

Who Is Atlas Holdings? Founded in 2002 by Andrew Bursky and Tim Fazio, Greenwich, CT-based Atlas Holdings owns and operates a global family of manufacturing and distribution businesses that together generate more than $20 billion in annual revenue. Atlas has experience in the office supplies sector through its LSC Communications unit, a leader in organizational solutions through brands such as Pendaflex.

Get the Full Report

Noble Capital Markets Research Report Monday, September 22, 2025

Companies contained in today’s report:

Information Services Group (III)/OUTPERFORM – Raising Price Target

Information Services Group (III/$5.38 | Price Target: $6.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Raising Price Target
Rating: OUTPERFORM

Raising Price Target. We are raising our price target on III shares to $6.50 from a prior $5, as III shares have exceeded our price target. The recent and expected future interest rate cuts, ongoing cost optimization efforts from clients, and the increasing pace of AI adoption will continue to drive ISG’s operating performance, in our view.

Valuation. At our $6.50 price target, III shares would trade at 1.4x our 2026 revenue estimate on an EV/sales basis, 10.7x on an EV/projected 2026 adjusted EBITDA basis, and 19.1x adjusted 2026 earnings. This compares to a peer group that trades at 1.3x, 10x, and 15.8x, respectively, consensus 2026 estimates.

Get the Full Report

Noble Capital Markets Research Report Friday, September 19, 2025

Companies contained in today’s report:

Ocugen (OCGN)/OUTPERFORM – OCU400 Licensing Agreement For Korea Completed

Ocugen (OCGN/$1.4 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
OCU400 Licensing Agreement For Korea Completed
Rating: OUTPERFORM

OCU400 Licensing Completed. Ocugen has announced the completion of a licensing agreement for Korea with Kwangdong Pharmaceutical, Co., Ltd., a diversified pharmaceutical company in the Republic of South Korea. This finalizes the term sheet announced in August with the 2Q25 business update. We have based our revenue expectations on US and Europe, with the Korea agreement adding additional cash upon the signing and downstream royalties.

Agreement Provides Cash, Milestones, and Royalties. The terms provide Ocugen with signing and near-term milestones of $7.5 million. Under the agreement, Ocugen will manufacture and supply OCU400 in exchange for a royalty of 25% of Net Sales plus sales milestones of $1 million for every $15 million in Net Sales, or roughly 32% per $15 million in sales. There are an estimated 7,000 retinitis pigmentosa (RP) patients in Korea, with an estimated market of about $180 million over the first 10 years of sales. We estimate these potential payments at about $65 million to Ocugen.

Get the Full Report

Noble Capital Markets Research Report Thursday, September 18, 2025

Companies contained in today’s report:

FreightCar America (RAIL)/OUTPERFORM – RAIL Adopts Stockholder Rights Plan
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – A Month of Awards
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Updating Our Sum-of-the-Parts Valuation; Increasing PT to US$1.05 or C$1.45

FreightCar America (RAIL/$8.71 | Price Target: $17)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
RAIL Adopts Stockholder Rights Plan
Rating: OUTPERFORM

Protecting the interests of all shareholders. Following a review of the company’s current ownership structure, FreightCar America announced that its Board of Directors adopted a limited-duration stockholder rights plan.The rights plan will expire on August 5, 2026, unless terminated earlier by the Board. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the company through open-market accumulation or other tactics without paying an appropriate control premium. The plan also ensures the Board has sufficient time to make informed decisions that protect the interests of the company and all RAIL shareholders.

Increasing 2026 estimates. We have increased our 2026 EBITDA and EPS estimates to $53.6 million and $0.65, respectively, from $53.2 million and $0.64. Our estimate update reflects stronger deliveries in the second half of the year, with a full-year estimate of 4,850 compared with our previous estimate of 4,800. We now expect quarterly deliveries of: 1Q: 982, 2Q: 1,200, 3Q: 1,284, and 4Q: 1,384. Previously we had assumed: 1Q: 1,346, 2Q: 1,275, 3Q: 1,058, and 4Q: 1,121.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$11.97 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Month of Awards
Rating: OUTPERFORM

More Business. Over the past month, Great Lakes continued to be awarded additional business, according to the Department of War’s daily contract awards release. In total, the announced awards (and recall not all awards are included in the daily notice), totaled approximately $80 million, demonstrating Great Lakes’ operating capabilities as well as the ongoing demand from the government.

September. Most recently, Great Lakes was awarded a $27.9 million firm-fixed-price contract for the removal and disposal of hopper dredge material. Work will be performed in Venice, Louisiana, with an estimated completion date of April 7, 2026. Fiscal 2025 civil operation and maintenance funds in the amount of $27.9 million were obligated at the time of the award.

Get the Full Report

Nicola Mining Inc. (HUSIF/$0.78 | Price Target: $1.05)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Updating Our Sum-of-the-Parts Valuation; Increasing PT to US$1.05 or C$1.45
Rating: OUTPERFORM

New Craigmont mining lease extensions. Nicola Mining Inc. (OTCQB: HUSIF, TSX.V: NIM) secured a five-year extension for six mining leases at its New Craigmont Property from the Ministry of Mining and Critical Minerals. The New Craigmont property encompasses over 10,800 hectares and is adjacent to Teck Resources Limited’s (NYSE: TECK, TSX: TECK.A and TECK.B) Highland Valley Copper Mine, the largest copper mine in Canada. On June 1, Nicola commenced a 4,000-to-5,000-meter diamond drill program at the New Craigmont project. The mining lease extension ensures continuity through the project’s lifecycle.

Shipments of gold concentrate. Earlier this month, Nicola announced that it had commenced shipping gold concentrate via a partnership with Talisker Resources Ltd. (TSX: TSK, OTCQX: TSKFF). Under a Mining, Milling, and Smelting Agreement, the parties sold 707 ounces of gold in August, generating gross proceeds of approximately US$2.3 million. Production benefited from upgrades to the Merritt Mill, including the installation of a large concentrator that optimized free gold recovery.

Get the Full Report

Noble Capital Markets Research Report Wednesday, September 17, 2025

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – Activist Shareholder Calls for Strategic Review
The GEO Group (GEO)/OUTPERFORM – A Renewal and Two New Contracts
V2X (VVX)/OUTPERFORM – Continuing to Lighten
Vince Holding Corp. (VNCE)/OUTPERFORM – A Closer Look Supports Our Favorable Outlook

Commercial Vehicle Group (CVGI/$1.94 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Activist Shareholder Calls for Strategic Review
Rating: OUTPERFORM

Call For A Review. In an amended Schedule 13D filing, investor Lakeview Opportunity Fund has communicated its views on the Company to the CVG management and Board on opportunities for value creation, including through a review process that explores strategic alternatives, including a sale of the Company.

Who Is Lakeview? With Managing Partner Ari Levy, Lakeview is a concentrated and opportunistic multi-strategy fund. The Fund focuses on underfollowed or ignored market areas, such as small and mid-cap value equities, niche Wall Street vehicles, options, and selective shareholder activism, where Lakeview helps companies, generally trading at significant discounts to private market value, unlock shareholder value.

Get the Full Report

The GEO Group (GEO/$22.04 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Renewal and Two New Contracts
Rating: OUTPERFORM

Contracts. The  Florida Department of Corrections has issued Notices of Intent to Award three managed-only contracts to GEO for the assumption of management and support services at the 985-bed Bay Correctional and Rehabilitation Facility and the 1,884-bed Graceville Correctional and Rehabilitation Facility and for the continuation of management and support services at the 985-bed Moore Haven Correctional and Rehabilitation Facility.

Details. The three contracts are expected to have an initial term of three years, effective  July 1, 2026, with unlimited two-year renewal option periods. On a combined basis, the three contracts are expected to generate approximately  $130 million in annualized revenues, including approximately  $100 million in new incremental annualized revenues for GEO. While the new contracts will not begin until next year, the new awards reflect GEO’s ability to provide the services demanded by its government partners, in our view.

Get the Full Report

V2X (VVX/$56.62 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Continuing to Lighten
Rating: OUTPERFORM

Another Sale. Private-equity firm American Industrial Partners (AIP), through its Vertex Aerospace subsidiary, sold another 1.7 million VVX shares on September 11th. According to the amended 13D filing, the shares were sold at a price of $52.203 per share through a Rule 144 sale. As we have stated in the past, we continue to expect AIP to sell off its V2X holding over time.

Ownership. Following the most recent share sale, AIP’s ownership is now 8,467,286 VVX shares, representing 26.9% of the outstanding common of V2X. This is down from the 18,591,866 VVX shares, or 61.1% of the then outstanding common, held by AIP just after the Vectrus/Vertex merger in July 2022.

Get the Full Report

Vince Holding Corp. (VNCE/$2.63 | Price Target: $4.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A Closer Look Supports Our Favorable Outlook
Rating: OUTPERFORM

Solid Q2 Results. The company reported Q2 revenue of $73.2 million, modestly beating our estimate of $72.0 million, and adj. EBITDA of $6.7 million, which strongly outperformed our estimate of $0.85 million by 685%. The strong adj. EBITDA was largely driven by management’s ability to execute on its tariff mitigation strategies, resulting in an improved gross profit margin.

Mitigating tariff impacts. Importantly, the company’s gross profit margin increased 300 basis points over the prior year period. The improvement was driven by lower product costing and higher pricing, contributing a 340 basis point improvement, as well as less discounting, which resulted in a 210 basis point improvement. However, the positive margin contributions were softened by tariff and freight impacts of 170 basis points and 100 basis points, respectively.

Get the Full Report

Noble Capital Markets Research Report Tuesday, September 16, 2025

Companies contained in today’s report:

Cadrenal Therapeutics (CVKD)/OUTPERFORM – Acquisition Builds The Pipeline With Anticoagulants In Development

Cadrenal Therapeutics (CVKD/$13.37 | Price Target: $45)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Acquisition Builds The Pipeline With Anticoagulants In Development
Rating: OUTPERFORM

Cadrenal Acquires Complimentary Cardiovascular Products. Cadrenal announced that it has acquired the anti-coagulant assets of eXlthera Pharmaceuticals. The products include frunexian, a Pre-Phase-2 anti-coagulant drug that inhibits a different step in the coagulation cascade from tecarfarin. Frunexian is in development for different indications and could extend Cadrenal’s product line to additional indications that are not served by current drugs. The acquisition also includes an oral formulation and other research-stage molecules.

Frunexian Has Several Distinguishing Features. The lead product from eXlthera is frunexian, a Factor XIa inhibitor. Most of the DOAC (direct-acting oral anticoagulant) class target Factor Xa and have been developed for long-term use on an outpatient basis. In contrast, frunexian targets Factor XIa, a different component of the coagulation cascade.

Get the Full Report

Noble Capital Markets Research Report Monday, September 15, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Favorable Time Charter Contract for the M/V Jonathan P
Greenwich LifeSciences, Inc. (GLSI)/OUTPERFORM – Fast Track Designation Gives Benefits Now And In The Future
Metals & Mining (Metals & Mining) – Insights from the Precious Metals Summit

Euroseas (ESEA/$63.97 | Price Target: $71)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Favorable Time Charter Contract for the M/V Jonathan P
Rating: OUTPERFORM

New time charter contract. Euroseas Ltd. announced a new time charter for the M/V Jonathan P at a gross daily rate of $25,000 for a minimum of 11 months, with an option to extend to a maximum of 12 months at the charterer’s option. The charter will commence on November 17th.

Attractive rate and improved charter coverage. The new contract is in direct continuation of the current charter and represents a $5,000 per day increase. It is expected to contribute approximately $5.7 million in EBITDA over the minimum contract period and raise Euroseas’ charter coverage to 100% for the remainder of 2025 and 70% for 2026.

Get the Full Report

Greenwich LifeSciences, Inc. (GLSI/$11.23 | Price Target: $45)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Fast Track Designation Gives Benefits Now And In The Future
Rating: OUTPERFORM

GLSI-100 Received Fast Track Designation. Greenwich LifeSciences announced that GLSI-100 has received Fast Track designation from the FDA. In the near term, this designation allows GLSI increased communications and more FDA meetings regarding regulatory requirements for its clinical trial data and use of biomarkers. Once the FLAMINGO-01 trial is completed, GLSI will be eligible to apply for Accelerated Approval and Priority Review, potentially shortening the time to market.

The Designation Mirrors The Trial Entry Criteria. GLSI-100 has received Fast Track Designation from the FDA for the treatment of “patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment with standard of care HER2/neu targeted therapy to improve invasive breast cancer free survival…” This includes the clinical trial entry criteria and endpoints for the current double-blind arms of the trial.

Get the Full Report

Metals & Mining
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Insights from the Precious Metals Summit

Precious Metals Summit. Noble Capital Markets was well represented at The Precious Metals Summit on September 9-12at the Beaver Creek Resort in Colorado. The conference attracted 1,700 registrants compared to approximately 1,200 in 2024 and included a broad spectrum of mining companies and institutional investors. Collectively, Noble had private meetings with over 70 company management teams during the invitation-only event.

Relative performance. Year-to-date through September 12,mining companies (as measured by the XME) appreciated 51.2% compared to a gain of 11.9% for the S&P 500 index. The VanEck Vectors Gold Miners (GDX) and Junior Gold Miners (GDXJ) ETFs were up 105.7% and 110.6%, respectively. Platinum, silver, and gold futures prices have gained 55.0%, 46.5%, and 39.6%, respectively, while copper, lead, and nickel increased 15.5%, 3.4% and 0.4%. Zinc declined 1.0%. Precious metals have led the charge as Central Banks around the world have added to global gold reserves, along with greater portfolio allocations among investors to precious metals as a hedge against rising inflation, a depreciating U.S. dollar, concerns about government debt, and increased geopolitical uncertainty. Moreover, there has been a desire among some nations to diversify away from the U.S. dollar as the benchmark reserve currency. Gold has become the global asset of choice to preserve value amid declining confidence in fiat currencies and an era of global monetary, geopolitical, and fiscal uncertainty.

Get the Full Report

Noble Capital Markets Research Report Friday, September 12, 2025

Companies contained in today’s report:

Nutriband (NTRB)/OUTPERFORM – Nutriband Reports 2Q26 With Product Progress
SEGG Media Corporation (SEGG)/OUTPERFORM – Leveraging Strong Brands As A Foundation For Growth

Nutriband (NTRB/$6.93 | Price Target: $15)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Nutriband Reports 2Q26 With Product Progress
Rating: OUTPERFORM

AVERSA Fentanyl Is Moving Forward. Nutriband reported results from 2Q26, ended July 31, 2025, with a loss of $2.12 per share. Revenues for 2Q26 were $0.6 million compared with $0.4 million in 2Q25. The increase was attributed to the expansion of contract manufacturing services in the Pocono Pharma division that produces kinesiology tape. Net loss was $2.0 million before Preferred Dividends of $21.8 million, bringing Net Loss Available To Shareholders to $23.8 million. Cash at the end of the quarter was $6.9 million.

Meeting With The FDA Later In September. The company has scheduled a meeting with the FDA on September 18, 2025, to discuss the upcoming Phase 1 clinical trial for AVERSA Fentanyl. This is a Type C Meeting, requested by the company to discuss product development. The meeting agenda includes the CMC (Chemistry, Manufacturing, and Controls) and other aspects of the Investigational New Drug Application (IND) using the 505(b)(2) route of regulatory approval.

Get the Full Report

SEGG Media Corporation (SEGG/$5.63 | Price Target: $20)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Leveraging Strong Brands As A Foundation For Growth
Rating: OUTPERFORM

Initiation of coverage with Outperform rating and $20 price target. We are initiating coverage on SEGG Media (NASDAQ: SEGG) with an Outperform rating and $20 target. The company is a development-stage operator of international sports and gaming businesses, anchored by valuable brand assets including Sports.com, Lottery.com, TicketStub.com, and Concerts.com.

Developmental stage. Formed out of Lottery.com’s collapse, SEGG has been reconstituted under new leadership with a defined focus on leveraging globally recognized brands. Management is pursuing an asset-light model combining digital platforms, sports media rights, and consumer venues. We believe this strategy positions SEGG to re-establish credibility and execute a compelling growth plan.

Get the Full Report

Noble Capital Markets Research Report Thursday, September 11, 2025

Companies contained in today’s report:

Lucky Strike Entertainment (LUCK)/OUTPERFORM – Initiated Debt Refinancing
Vince Holding Corp. (VNCE)/OUTPERFORM – Delivered A Strong Quarter

Lucky Strike Entertainment (LUCK/$9.6 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Initiated Debt Refinancing
Rating: OUTPERFORM

Strategic update. On September 10, the company announced that its wholly-owned subsidiary Kingpin Intermediate Holdings LLC initiated a private offering of  $700 million in new senior secured notes, due in 2032. Concurrently, the company launched a refinancing of its corporate term loan and revolving credit facility. The company expects the initial amount of the refinanced term loan and revolving credit facility to be $1 billion and $400 million, respectively. 

Use of capital. Importantly, the net proceeds from the new debt offering and the refinanced credit facilities are earmarked for retiring the company’s existing term loan, revolving credit facility, and bridge loan, which was used to acquire 58 real estate assets in July. Furthermore, the remaining proceeds will be used to fund the company’s strategic initiatives.

Get the Full Report

Vince Holding Corp. (VNCE/$1.66 | Price Target: $4.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Delivered A Strong Quarter
Rating: OUTPERFORM

Solid Q2 Results. The company reported Q2 revenue of $73.2 million, modestly beating our estimate of $72.0 million, and adj. EBITDA of $6.7 million, which strongly outperformed our estimate of $0.85 million by 685%, as illustrated in Figure #1 Q2 Results. The strong adj. EBITDA was largely driven by management’s ability to execute on its tariff mitigation strategies, resulting in an improved gross profit margin.

Mitigating tariff impacts. Importantly, the company’s gross profit margin increased 300 basis points over the prior year period. The improvement was driven by lower product costing and higher pricing, contributing a 340 basis point improvement, as well as less discounting, which resulted in a 210 basis point improvement. However, the positive margin contributions were softened by tariff and freight impacts of 170 basis points and 100 basis points, respectively.

Get the Full Report

Noble Capital Markets Research Report Tuesday, September 9, 2025

Companies contained in today’s report:

Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Positioned To End YE2025 With Strong Products and Pipeline Development

Gyre Therapeutics, Inc (GYRE/$7.89 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Positioned To End YE2025 With Strong Products and Pipeline Development
Rating: OUTPERFORM

Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025.

Hydronidone Data Showed Efficacy and Proof of Concept. The pivotal Phase 3 trial testing Hydronidone in Chronic Hepatitis B-associated fibrosis has met its primary endpoint of fibrosis regression. The study was conducted in China, and an application for approval by the NMPA (the Chinese regulatory authority) is planned for 3Q2025. Hydronidone has received Breakthrough Therapy Designation, allowing for accelerated review. We expect approval in 2H2026, followed by launch in FY2027.

Get the Full Report

Release – Newsmax Announces Crypto Plan for Asset Reserve

Research News and Market Data on NMAX

October 16, 2025

Company’s Board Authorizes Strategic Purchases of up to $5 Million of Bitcoin and Trump Coin

BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that the Company’s Board of Directors has authorized a strategic purchase plan of up to $5 million to purchase Bitcoin and Trump Coin over the next 12 months, subject to market conditions.

Newsmax expects to join more than 100 public companies that hold Bitcoin or other cryptocurrencies on their balance sheets. According to BitcoinTreasuries data, public company-held coin represents over 4.7% of total Bitcoin in circulation.

Newsmax also plans to add official Trump Coin to its strategic crypto reserve. The popular meme coin was launched earlier this year by President Trump and the circulating coin value exceeds $1.2 billion today with a total coin market value of around $6 billion, according to figures from Coinbase.

“Bitcoin is fast becoming the gold standard of cryptocurrency, and we believe it would be an important company marker to add this asset to our company reserves,” Newsmax CEO Christopher Ruddy said.

“We are also excited to add Trump Coin to our cryptocurrency plan, as we believe the coin’s value should track the success of the Trump presidency, which so far has been impressive,” Ruddy continued.

After making such a purchase, Newsmax expects to be the first NYSE company to purchase Trump Coin.

Newsmax anticipates making the first tranche of cryptocurrency purchases in the near future. Additional cryptocurrency acquisitions will be evaluated based on market conditions, operational requirements and strategic objectives. The Company maintains flexibility to adjust its digital asset strategy as market conditions evolve.

Newsmax has established comprehensive protocols for digital asset custody and management, partnering with leading institutional cryptocurrency services providers to ensure secure storage and handling of its cryptocurrency reserves.

This past March, President Trump announced the establishment of a Strategic Bitcoin Reserve for the United States. The fund is expected to begin with forfeited government Bitcoin and will grow with a Digital Asset Stockpile made up of other cryptocurrencies.

Newsmax listed on the NYSE in March 2025 after a historic Private Preferred raise and Regulation A+ IPO offering that successfully raised $300 million.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major cable stations, as well as a major satellite system. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

Release – NN, Inc. to Hold Third Quarter 2025 Earnings Conference Call on Thursday, October 30, 2025

Research News and Market Data on NNBR

CHARLOTTE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it will release its third quarter 2025 financial results for the period ended September 30th, 2025, after the close of the market on Wednesday, October 29th, 2025. The Company will hold a related conference call on Thursday, October 30th, 2025, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-877-255-4315 and from outside the U.S. at 1-412-317-6579.

The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through October 31st, 2026.

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

Investor Relations:
Joe Caminiti or Stephen Poe
NNBR@alpha-ir.com
312-445-2870

Source: NN, Inc.

Release – ACCO Brands Corporation Announces Third Quarter 2025 Earnings Webcast

Research News and Market Data on ACCO

10/17/2025

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that it will release its third quarter 2025 earnings after the market close on October 30, 2025. The Company will host a conference call and webcast to discuss the results on October 31 at 8:30 a.m. EST. The webcast can be accessed through the Investor Relations section of www.accobrands.com and will be available for replay.

About ACCO Brands Corporation

ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found atwww.accobrands.com.

For further information:

Chris McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406

Source: ACCO Brands Corporation

Release – Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Research News and Market Data on TNXP

NX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox

TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models

Data support advancement of TNX-801 toward clinical development

CHATHAM, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”) presented data in an oral presentation at the World Vaccine Congress–Europe 2025, held October 14–16, 2025, in Amsterdam, the Netherlands. A copy of the Company’s presentation, titled “Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine,” is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

“Vaccines remain a cornerstone of pandemic preparedness and biodefense,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The data presented in Amsterdam support the potential of TNX-801 as a next-generation orthopoxvirus vaccine candidate with the ability to confer durable protection. We believe TNX-801 has the potential to strengthen global readiness for emerging and re-emerging poxvirus threats.”

TNX-801 is a live, attenuated, minimally replicative investigational vaccine candidate based on horsepox virus and is being developed to protect against mpox (monkeypox) and smallpox. Preclinical data presented by Sina Bavari, Ph.D., Executive Vice President, Infectious Disease Research at Tonix Pharmaceuticals, demonstrated that TNX-801 produced durable immune protection following a single dose and was well tolerated across multiple routes of administration, including percutaneous, subcutaneous, and intramuscular delivery. TNX-801 elicited strong neutralizing antibody responses and protected animals from clinical disease and mortality following mpox challenge in non-human primate, rabbit, and murine models. Immunogenicity and durability were observed for at least 14 months post-vaccination.

“We are encouraged by the consistency and durability of the TNX-801 data across multiple preclinical models,” said Dr. Sina Bavari. “We are also excited by the opportunity to evaluate microneedle patch technology as a novel delivery platform to simplify administration and expand vaccine accessibility in future development stages.”

About TNX-801*
TNX-801 (recombinant horsepox virus) is an, attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. Tonix reported positive preclinical efficacy data, demonstrating that TNX-801 vaccination protected non-human primates against lethal challenge with monkeypox. After a single dose vaccination, TNX-801 prevented clinical disease and lesions and decreased shedding in the mouth and lungs of non-human primates. The findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner’s vaccine, which eradicated smallpox and kept mpox out of the human population. TNX-801 is based on synthesized horsepox which is believed to be more closely related to Dr. Jenner’s vaccine than 20th century vaccinia viruses. Smallpox vaccines descended from Jenner’s vaccine used prior to 1900 would be called horsepox by modern nomenclature.. Tonix has received official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-801 as a potential vaccine to protect against mpox disease and smallpox. Tonix has announced a collaboration with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study of TNX-801 in Kenya. The Company believes TNX-801 has the potential to make a global impact on mpox and the risk of smallpox because of its durable T-cell immune response, the potential to manufacture at scale, and the use of a lower dose than non-replicating vaccines. The FDA-approved non-replicating mpox vaccine Jynneos® requires two doses and provides a relatively short duration of protection. FDA also recently approved ACAM2000, a live, replicating vaccinia vaccine for prevention of mpox. ACAM200 is a clone from DryVax®, a 20th century vaccinia vaccine derived from the NYCBH strain. Pre-clinical results from an mRNA vaccine recently showed some protection from a Clade I monkeypox challenge, but with multiple break-through lesions in vaccinated animals.

Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix has received FDA approval for TonmyaTM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a monoclonal antibody for the seasonal prevention of Lyme Disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris 
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contact 
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.
CONTRAINDICATIONS
TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.
With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.
During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.
In patients with hyperthyroidism.
WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.
Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.
Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.
Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.
CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.
Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.
Other serotonergic drugs: Serotonin syndrome has been reported.
CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.
Tramadol: Seizure risk may be enhanced.
Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).
Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.
Pediatric use: The safety and effectiveness of TONMYA have not been established.
Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.
Please see additional safety information in the full Prescribing Information.
To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: Tonix Pharmaceuticals Holding Corp.

Release – Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Research News and Market Data on ELDN

Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET

IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the American Society of Nephrology’s upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlight topline results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.

Details of the oral presentation are below:

Title:  Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW Trial
Presenter:  Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
Abstract Publication Number: TH-OR089
Session Title:  Late-Breaking Research Orals – 1
Session Date and Time: November 6, 2025, from 4:30 p.m. to 6:00 p.m. CT
Session Room: Grand Ballroom C (Convention Center)
Presentation Time: 5:30 p.m. to 5:42 p.m. CT

Conference Call

Eledon will hold a conference call on November 7, 2025 at 8:00 a.m. Eastern Time to discuss the Phase 2 BESTOW trial results presented at Kidney Week. The dial-in numbers are 1-800-717-1738 for domestic callers and 1-646-307-1865 for international callers. The conference ID is 92427. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.eledon.com. The webcast will be archived on the website following the completion of the call.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedInTwitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

Boston Scientific to Acquire Nalu Medical for $533 Million to Expand Chronic Pain Portfolio

Deal strengthens neuromodulation lineup with battery-free neurostimulation system

Boston Scientific Corporation (NYSE: BSX) announced Friday that it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company specializing in minimally invasive treatments for chronic pain.

Under the terms of the agreement, Boston Scientific will pay approximately $533 million in cash for the remaining equity of Nalu Medical that it does not already own. The company has been a strategic investor in Nalu since 2017. The transaction, expected to close in the first half of 2026, remains subject to customary closing conditions.

Nalu’s flagship product, the Nalu Neurostimulation System, is designed to deliver targeted relief for adults suffering from severe, intractable chronic pain of peripheral nerve origin — including pain in the shoulder, lower back, and knee. The system delivers mild electrical impulses to interrupt pain signals before they reach the brain and features a miniaturized, battery-free implantable pulse generator powered wirelessly by an external therapy disc and controlled via a smartphone app.

The U.S. Food and Drug Administration cleared the Nalu system in 2019. Results from the COMFORT and COMFORT 2 clinical trials demonstrated significant and sustained pain reduction, with 87% of participants in the first trial reporting more than 50% pain reduction at 12 months and 79% in the second trial achieving an average 64% reduction at six months. Real-world data from over 2,000 patients reinforced these outcomes, with 94% experiencing clinically meaningful improvement.

“Peripheral nerve stimulation is an exciting field with a significant unmet patient need,” said Jim Cassidy, president of Neuromodulation at Boston Scientific. “Adding Nalu Medical’s highly differentiated technology complements our existing therapies — including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation — and enables us to deliver advanced pain relief options to a wider variety of patient populations.”

Boston Scientific expects Nalu to generate over $60 million in sales in 2025 and to deliver growth exceeding 25% in 2026. The acquisition is projected to be immaterial to adjusted EPS in 2026, slightly accretive in 2027, and increasingly accretive thereafter. On a GAAP basis, the company expects the deal to be more dilutive due to amortization and acquisition-related expenses.

Nalu Medical, headquartered in Carlsbad, California, has been repeatedly recognized for innovation, including being named among the top 100 new products globally by R&D Magazine and winning multiple Medical Design Excellence Awards. Its compact, modular neurostimulation system represents a next-generation approach to chronic pain management by reducing the need for frequent interventions and improving patient comfort.

Boston Scientific, based in Marlborough, Massachusetts, is a global medical technology leader with a 45-year history of advancing science and developing solutions that improve patient outcomes across multiple therapeutic areas.

Rani Therapeutics Soars on $1 Billion Chugai Partnership and $60 Million Private Placement

Massive trading volume follows dual announcements boosting balance sheet and strategic outlook

Rani Therapeutics Holdings (NASDAQ: RANI) surged more than 200% in early trading Friday, with over 240 million shares changing hands — a dramatic increase from its three-month average daily volume of just over 600,000. The spike follows back-to-back announcements of a major collaboration agreement with Chugai Pharmaceutical Co. worth up to $1.085 billion and an oversubscribed $60.3 million private placement.

The collaboration with Japan-based Chugai — a member of the Roche Group — covers multiple high-value therapeutic programs, including those in rare diseases and immunology. Under the deal, Rani will receive a $10 million upfront payment and is eligible for up to $75 million in technology transfer and development milestones, $100 million in sales milestones, and single-digit royalties on future product sales. Chugai also has the option to partner on up to five additional drug targets under similar terms, which could bring the total potential deal value to more than $1 billion.

“This partnership represents a convergence of Rani’s cutting-edge oral delivery platform and Chugai’s expertise in antibody development,” said Rani Therapeutics CEO Talat Imran. “We’re uniting two powerful scientific teams to develop oral therapies that could redefine treatment for rare and immunologic diseases globally.”

Alongside the collaboration, Rani announced a $60.3 million private placement priced at-the-market under Nasdaq rules, led by new investor Samsara and joined by RA Capital Management, Anomaly, Special Situations Funds, Invus, and Rani’s Executive Chairman Mir Imran. The oversubscribed financing includes 42.6 million shares of Class A common stock and 82.4 million pre-funded warrants, each accompanied by warrants to purchase additional shares.

Rani said the net proceeds from the offering, combined with the upfront and milestone payments from Chugai, will extend its operating runway into 2028 and fund advancement of its RaniPill® platform — a proprietary oral delivery system designed to replace subcutaneous or intravenous biologic injections with oral capsules.

“We believe this additional financing from leading biotech investors reflects growing confidence in our strategy,” said Imran. “Together, this financing and our strategic partnership with Chugai mark a pivotal moment for Rani.”

At the closing of the financing, Samsara and Anomaly will each have the right to appoint a member to Rani’s board of directors.

Rani Therapeutics, based in San Jose, California, is a clinical-stage biotherapeutics company focused on developing orally administered biologics and drugs using its RaniPill® platform technology.

Nicola Mining Inc. (HUSIF) – Hitting All the Right Notes


Thursday, October 16, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Treasure Mountain exploration. Nicola Mining Inc. (OTCQB: HUSIF, TSXV: NIM) provided an update on its plan for 2026 exploration drilling at the Treasure Mountain Silver Project. The area of exploration interest is northwest of the currently suspended mine and consists of several northeast to southwest trending and steeply dipping sulphide-rich veins. Results from previous exploration work confirmed the presence of vein-hosted silver, copper, lead, zinc, and gold, providing support for initial diamond drilling to establish the width of the trend and mineralization at depth.

Recent gold sales. Talisker Resources (OTCQB: TSKFF, TSX: TSK) has an agreement to process run-of-mine material from its Mustang Mine at Nicola’s Merritt Mill. For the quarter ending on September 30, a total of 1,569 ounces of gold were produced from Talisker’s Mustang Mine. Nicola receives a share of the gross profit from milling ore sourced from Talisker Resources Ltd. Blue Lagoon Resources Inc. (OTCQB: BLAGF, CSE: BLLG) recently announced an amended mining and milling partnership agreement with Nicola Mining, extending the partnership to a 10-year term. The agreement secures a long-term processing solution for mineralized material from Blue Lagoon’s high-grade Dome Mountain Gold Project.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comstock (LODE) – Strategic Acquisition Expands Nevada Mining Footprint


Thursday, October 16, 2025

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition of Haywood Quarry. Comstock completed the acquisition of the Haywood Quarry industrial and mineral properties from Decommissioning Services LLC. The 190-acre property, located in Lyon County, Nevada, includes available power, water, and direct access to U.S. Highway 50. The site historically hosted gold mining and aggregate operations and is strategically contiguous to Comstock’s flagship Dayton gold and silver resource.

Transaction terms. Comstock acquired the property for a total of $2.2 million in cash and stock from Decommissioning Services LLC. The transaction provides Comstock with full ownership and control of the Haywood industrial and mineral properties, integrating them into its broader Lyon County mineral estate. The purchase also enhances Comstock’s strategic flexibility in advancing mine planning, resource development, and reclamation initiatives at the Dayton complex.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Highlights from the Noble Emerging Growth Virtual Conference


Thursday, October 16, 2025

ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble virtual conference. Alliance recently participated in Noble Capital Markets’ Emerging Growth Virtual Conference. The fundamental outlook for ARLP’s coal operations and oil and gas royalty business, the two largest drivers of cash flow, remains favorable. The coal and electric power generation industries are expected to benefit from Trump Administration policies that seek to assure affordable, reliable, and secure energy sources to meet growing demand for electricity. Through 2Q 2025, Alliance has invested $758 million in its oil and gas royalty business that has generated cumulative segment adjusted EBITDA of $622 million. While they have grown the oil and gas royalty business without the use of leverage, they do have the ability to employ leverage for larger acquisitions. A link to the presentation is here.

Capital allocation. Management takes a long-term view when making capital allocation decisions, with balance sheet strength being the highest priority. The next priority is investing in its coal business to ensure it remains an efficient and low-cost producer. The third priority is reinvesting the cash flow generated by the oil and gas business to make accretive acquisitions. Lastly, the company intends to return capital to shareholders, including attractive cash distribution payments, while ensuring flexibility to fund growth opportunities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Metals to Acquire Foley Products in $1.84 Billion All-Cash Deal

Commercial Metals Company (NYSE: CMC) announced it will acquire Foley Products Company, a leading supplier of precast concrete solutions in the southeastern United States, for $1.84 billion in cash. The move marks CMC’s formal entry into the precast industry and follows its recently announced acquisition of Concrete Pipe & Precast (CP&P).

CMC said the acquisitions of Foley and CP&P will establish the company as the third largest precast platform in the U.S., operating 35 facilities across 14 states, and a market leader in the Mid-Atlantic and Southeast regions.

“The acquisition of Foley presents a unique opportunity to create immediate scale for our precast platform while adding a best-in-class business with industry-leading margins to CMC’s portfolio,” said Peter Matt, President and Chief Executive Officer of Commercial Metals. “We believe precast has significant value creation potential for CMC, and the addition of Foley will help unlock further upside from our pending acquisition of CP&P.”

Foley Products is known for its industry-leading EBITDA margins and cash flow generation, supported by well-established best practices and a broad portfolio of precast solutions. The purchase price represents a 10.3x multiple of Foley’s forecasted 2025 EBITDA, or roughly 9.2x when factoring in expected cash tax benefits.

The transaction is expected to be immediately accretive to earnings per share and free cash flow, with $25 million to $30 million in annual run-rate synergies anticipated by the third year. Synergies will primarily stem from operational efficiencies, cost reductions, and cross-selling opportunities across complementary geographic markets.

Following the integration of Foley and CP&P, CMC expects its core EBITDA margin to increase by approximately 210 basis points, with about 32% of total pro forma segment adjusted EBITDA generated by its Emerging Businesses Group and precast platform — up from 15% in fiscal 2025. The company also expects strong free cash flow generation, targeting a reduction in net leverage from 2.7x to below 2.0x within 18 months.

CMC emphasized that the precast concrete market — estimated at $30 billion in annual U.S. revenue — provides a strong strategic fit, leveraging the company’s existing relationships in early-stage construction and expanding its reach into mission-critical infrastructure applications.

Precast components, such as concrete pipes and utility structures, are manufactured off-site in controlled environments, offering faster installation times, improved quality, and reduced labor needs compared to traditional pour-in-place methods.

Praxis Precision Medicines Reports Positive Topline Phase 3 Data for Ulixacaltamide in Essential Tremor, Shares Surge

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced positive topline results from its Essential3 Phase 3 program evaluating ulixacaltamide HCl for the treatment of essential tremor (ET). The company reported that both pivotal studies met their pre-specified primary endpoints, with all key secondary endpoints also achieved, and ulixacaltamide was generally well tolerated with no drug-related serious adverse events.

In the parallel-group study (Study 1), patients treated with ulixacaltamide demonstrated a mean improvement of 4.3 points from baseline in the Modified Activities of Daily Living 11 (mADL11) at Week 8 (p<0.0001). All key secondary endpoints, including rate of disease improvement over 12 weeks, Patient Global Impression of Change (PGI-C), and Clinical Global Impression of Severity (CGI-S), were statistically significant (p<0.001).

In Study 2, a randomized-withdrawal design, patients maintained superior treatment effects on ulixacaltamide versus placebo (p=0.0369), with the first key secondary endpoint — rate of disease improvement — also demonstrating a statistically significant benefit (p=0.0042).

“Patients in the Essential3 program had been living with essential tremor for an average of 30 years, with worsening symptoms and no effective treatment options,” said Marcio Souza, President and CEO of Praxis Precision Medicines. “The strong results underscore the large unmet need for a therapy like ulixacaltamide. We look forward to discussing a potential NDA with the FDA in the near term.”

The Essential3 program enrolled over 700 patients across two studies using a decentralized design in the United States. Study 1 was a 12-week, double-blind, placebo-controlled trial evaluating change in mADL11 at Week 8. Study 2 enrolled stable responders to ulixacaltamide and assessed maintenance of effect during a four-week randomized-withdrawal phase.

Ulixacaltamide is a selective T-type calcium channel inhibitor designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit, which is associated with tremor activity. The therapy is the most advanced program in Praxis’ Cerebrum™ small molecule platform.

Essential tremor is the most common movement disorder in the U.S., affecting roughly 7 million people, and currently has limited treatment options. Propranolol is the only approved therapy, with limited efficacy and tolerability, leaving a substantial patient population untreated.

Following the announcement, PRAX shares surged more than 200% in early trading, with roughly 2.8 million shares traded, far exceeding the three-month daily average of 449,000 shares. Praxis has submitted a pre-NDA meeting request to the FDA and plans to continue advancing ulixacaltamide toward regulatory submission.